Welcome to STN International! Enter x:x

LOGINID: SSPTAKAB1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Web Page for STN Seminar Schedule - N. America
NEWS
NEWS
        AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS
                EPFULL enhanced with full implementation of EPC2000
        OCT 07
NEWS 4 OCT 07 Multiple databases enhanced for more flexible patent
                number searching
NEWS 5
        OCT 22 Current-awareness alert (SDI) setup and editing
                enhanced
        OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
NEWS 6
                Applications
NEWS
        OCT 24 CHEMLIST enhanced with intermediate list of
                pre-registered REACH substances
        NOV 21 CAS patent coverage to include exemplified prophetic
NEWS
    8
                substances identified in English-, French-, German-,
                and Japanese-language basic patents from 2004-present
NEWS 9
        NOV 26 MARPAT enhanced with FSORT command
NEWS 10
        NOV 26 MEDLINE year-end processing temporarily halts
                availability of new fully-indexed citations
NEWS 11 NOV 26 CHEMSAFE now available on STN Easy
NEWS 12 NOV 26 Two new SET commands increase convenience of STN
                searching
        DEC 01
NEWS 13
                ChemPort single article sales feature unavailable
NEWS 14
        DEC 12
                GBFULL now offers single source for full-text
                coverage of complete UK patent families
NEWS 15
        DEC 17
                Fifty-one pharmaceutical ingredients added to PS
NEWS 16
        JAN 06
                The retention policy for unread STNmail messages
                will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 17
        JAN 07
                WPIDS, WPINDEX, and WPIX enhanced Japanese Patent
                Classification Data
```

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 09:57:28 ON 13 JAN 2009

=> file reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.22 0.22

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 09:57:36 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by ${\tt InfoChem.}$

STRUCTURE FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4 DICTIONARY FILE UPDATES: 11 JAN 2009 HIGHEST RN 1093181-04-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\STNEXP\Queries\10522250 updated.str



8.1

12 Q.x 1

chain nodes :
9 11 12
ring nodes :

1 2 3 4 5 6 7 8

chain bonds :
2-9 11-12
ring bonds :

1-2 1-5 2-3 3-4 3-6 4-5 4-8 6-7 7-8

exact/norm bonds :

1-2 1-5 2-3 2-9 3-4 3-6 4-5 4-8 6-7 7-8 11-12

isolated ring systems :

containing 1 :

G1:0, S, N, SO2, [*1]

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS 12:CLASS

L1 STRUCTURE UPLOADED

=> d L1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.48 0.70

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:57:57 ON 13 JAN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Jan 2009 VOL 150 ISS 3 FILE LAST UPDATED: 12 Jan 2009 (20090112/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l1 sss full

REG1stRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress... Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

FULL SEARCH INITIATED 09:58:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 651 TO ITERATE

100.0% PROCESSED 651 ITERATIONS 550 ANSWERS

SEARCH TIME: 00.00.01

L2 550 SEA SSS FUL L1

L3 22 L2

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2008:888806 CAPLUS Full-text

DOCUMENT NUMBER: 149:200948

TITLE: Preparation of substituted arylamine derivatives

useful for the treatment of pain, inflammation and

cancer

INVENTOR(S): Barbosa, Joseph; Baugh, Simon D. P.; Han, Qiang;

Lombardo, Victoria K.; Nguyen, Huy Van; Pabba, Praveen

K.; Terranova, Kristen M.

PATENT ASSIGNEE(S): Lexicon Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 111pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:	TENT	NO.			KIND		DATE			APPL	ICAT	DATE						
	WO 2008089307 WO 2008089307				A2 A3		20080724 20081106		,	wo 2	008-	JS51		20080117				
	W:	CA, FI, KG, ME, PL,	CH, GB, KM, MG, PT,	CN, GD, KN, MK, RO,	CO, GE, KP, MN, RS,	CR, GH, KR, MW, RU,	AT, CU, GM, KZ, MX, SC, UG,	CZ, GT, LA, MY, SD,	DE, HN, LC, MZ, SE,	DK, HR, LK, NA, SG,	DM, HU, LR, NG, SK,	DO, ID, LS, NI, SL,	DZ, IL, LT, NO, SM,	EC, IN, LU, NZ, SV,	EE, IS, LY, OM,	EG, JP, MA, PG,	ES, KE, MD, PH,	
	R₩:	AT, IE, TR, TG,	BE, IS, BF, BW,	BG, IT, BJ, GH,	CH, LT, CF, GM,	CY, LU, CG, KE,	CZ, LV, CI, LS,	DE, MC, CM, MW,	DK, MT, GA, MZ,	EE, NL, GN, NA,	ES, NO, GQ, SD,	FI, PL, GW, SL,	FR, PT, ML, SZ,	GB, RO, MR, TZ,	SE, NE,	SI, SN,	SK, TD,	

US 20080194557 A1 20080814 US 2008-15714 20080117 PRIORITY APPLN. INFO.: US 2007-881090P P 20070118

OTHER SOURCE(S): MARPAT 149:200948

 \mathbb{Q}^{1} \mathbb{Q}^{2} \mathbb{Q}^{2}

This invention relates to methods of treating, managing and preventing pain, AΒ inflammation, cancer, and ocular diseases and disorders, and to compds. and pharmaceutical compns. useful in such methods. Compds. of formula I [Q1 =CR1, CHR1, N or NR1; Q2 = CR1, CHR1, N or NR1; X = S, O, C(R4R5) or N(R4); Y =C(R4), C(R4R5), N or N(R4); A = bond, CH2, C(O) or SO2; R1 and R3 independently = H, CN, NO2, halo, (un)substituted alkyl, aryl, alkylaryl, arylalkyl, etc.; R2 = H or (un)substituted alkyl; R4 and R5 independently = H or (un)substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl; n = 1-4; m = 1-5], and their pharmaceutically acceptable salts or solvates, are prepared and disclosed as potent $\Delta 5$ -desaturase inhibitors. Thus, e.g., N-(3-chlorophenyl)isoquinolin-1amine was prepared by condensation reaction of 1-chloroisoquinoline with 3chloroaniline. I are potent $\Delta 5$ -desaturase inhibitors, e.g., some compds. had IC50 values of < 250 nM. Certain compds. inhibited $\Delta 5$ -desaturase in vivo by greater than 75% at about 60 mpk.


IT 1041614-39-4P, (5-Chloro-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl)(3-chlorophenyl)amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted arylamine derivs. useful for the treatment of pain, inflammation and cancer)

RN 1041614-39-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 5-chloro-N-(3-chlorophenyl)-1-methyl-(CA INDEX NAME)



L3 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2008:887545 CAPLUS Full-text

DOCUMENT NUMBER: 149:200945

TITLE: Preparation of substituted arylamine derivatives

useful for the treatment of body composition disorders

INVENTOR(S): Barbosa, Joseph; Baugh, Simon D. P.; Han, Qiang;

Lombardo, Victoria K.; Nguyen, Huy Van; Pabba, Praveen

K.; Terranova, Kristen M.

PATENT ASSIGNEE(S): Lexicon Pharmaceuticals, Inc., USA

SOURCE: PCT Int. Appl., 106pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

P.F	ATENT :	NO.			KIND		DATE			APPL	ICAT		DATE				
WC	WO 2008089310					_	20080724		•	WO 2	008-		20080117				
WC	2008	008089310			A3		20081030										
	W:	ΑE,	AG,	AL,	AM,	ΑO,	ΑT,	ΑU,	ΑZ,	BA,	BB,	ВG,	BH,	BR,	BW,	BY,	BZ,
		CA,	CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DO,	DZ,	EC,	EE,	EG,	ES,
		FI,	GB,	GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,
		KG,	KM,	KN,	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,
		ME,	MG,	MK,	MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NΖ,	OM,	PG,	PH,
		PL,	PT,	RO,	RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,
		TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	ZA,	ZM,	ZW			
	RW:	ΑT,	BE,	ВG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HR,	HU,
		ΙE,	IS,	ΙT,	LT,	LU,	LV,	MC,	MT,	NL,	NO,	PL,	PT,	RO,	SE,	SI,	SK,
		TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	ΝE,	SN,	TD,
		TG,	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,
		AM,	ΑZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	AP,	EA,	EP,	OA			
US	US 20080200458						A1 20080821				008-	1572	8	20080117			
PRIORIT	RIORITY APPLN. INFO.:									US 2	007-	8809	P 20070118				
OTHER S	THER SOURCE(S):						MARPAT 149:200945										
GT																	

$$(R^1)_n$$
 Q^2 R^2 $(R^3)_m$

AB This invention relates to methods of treating, managing and preventing body composition disorders, such as obesity and diabetes, and to compds. and pharmaceutical compns. useful in such methods. Compds. of formula I [Q1 = CR1, CHR1, N or NR1; Q2 = CR1, CHR1, N or NR1; X = S, O, C(R4R5) or N(R4); Y = SC(R4), C(R4R5), N or N(R4); A = bond, CH2, C(O) or SO2; R1 and R3independently = H, CN, NO2, halo, (un) substituted alkyl, aryl, alkylaryl, arylalkyl, etc.; R2 = H or (un)substituted alkyl; R4 and R5 independently = H or (un) substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl; n = 1-4; m = 1-5], and their pharmaceutically acceptable salts or solvates, are prepared and disclosed as potent $\Delta 5$ -desaturase inhibitors. Thus, e.g., N-(3-chlorophenyl)isoquinolin-1amine was prepared by condensation reaction of 1-chloroisoquinoline with 3chloroaniline. I are potent $\Delta 5$ -desaturase inhibitors, e.g., some compds. had IC50 values of < 250 nM. Certain compds. inhibited $\Delta 5$ -desaturase in vivo by greater than 75% at about 60 mpk.


IT 1041614-39-4P, (5-Chloro-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl)(3chlorophenyl)amine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation of substituted arylamine derivs. useful for the treatment of pain, inflammation and cancer)

RN 1041614-39-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 5-chloro-N-(3-chlorophenyl)-1-methyl-(CA INDEX NAME)



L3 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2008:173028 CAPLUS Full-text

DOCUMENT NUMBER: 148:426791

TITLE: Synthesis of 3-substituted-1-methyl-1H-thieno[2,3-

c]pyrazoles

AUTHOR(S): Toto, Patrick; Chenault, Jacques; El Hakmaoui, Ahmed;

Akssira, Mohamed; Guillaumet, Gerald

CORPORATE SOURCE: Analytic and Organic Chemistry Institute, UMR CNRS,

University of Orleans, Orleans, Fr.

SOURCE: Synthetic Communications (2008), 38(5), 674-683

CODEN: SYNCAV; ISSN: 0039-7911

PUBLISHER: Taylor & Francis, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:426791

AB The authors reported a simple and practical six-step synthesis of new 1-methyl-1H-thieno[2,3-c]pyrazoles from 3-amino-1H-pyrazole-4-carboxylic acid Et ester.

IT 1017802-97-9P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of substituted-methyl-thienopyrazoles from aminopyrazole-carboxylic acid Et ester in six-steps)

RN 1017802-97-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-4-[[5-(ethoxycarbonyl)-4-hydroxy-1-methyl-1H-thieno[2,3-c]pyrazol-3-yl]amino]-1-methyl-, ethyl ester (CA INDEX NAME)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2007:1146039 CAPLUS Full-text

DOCUMENT NUMBER: 147:440293

TITLE: Use of thienopyrazole derivative ABL kinase inhibitors

for the treatment of resistant tumors, and screening

method

INVENTOR(S): Fancelli, Daniele; Isacchi, Antonella; Modugno,

Michele; Moll, Jurgen; Rusconi, Luisa; Soncini,

Chiara; Lupi, Rosita

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy

SOURCE: PCT Int. Appl., 43pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	ATENT	NO.			KIN	D	DATE		APPLICATION NO.										
		2007113198							WO 2007-EP53013										
W		2007113198					2008												
	₩:	ΑE,	AG,	AL,	ΑM,	AT,	ΑU,	AΖ,	BA,	BB,	BG,	BH,	BR,	BW,	BY,	BZ,	CA,		
		CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,		
		GD,	GE,	GH,	GM,	GT,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,		
		KN,	KP,	KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LY,	MA,	MD,	MG,	MK,		
		MN,	MW,	MX,	MY,	MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,		
		RS,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SV,	SY,	ΤJ,	TM,	TN,	TR,	TT,		
		TZ,	UA,	UG,	US,	UΖ,	VC,	VN,	ZA,	ZM,	ZW								
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	IT,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,		
		ВJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,		
		GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,		
		BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑP,	EA,	EP,	OA							
EI	2007	380			A2		2008	1231		EP 2	007-	7274	20070329						
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	IT,	LI,	LT,	LU,	LV,	MC,	MT,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,		
		AL,	BA,	HR,	MK,	RS													
PRIORI:	PRIORITY APPLN. INFO.:									EP 2	i	A 20060330							
									WO 2007-EP53013							W 20070329			

OTHER SOURCE(S): MARPAT 147:440293

The invention provides low mol. weight compds., namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compds. are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor- resistant T315I ABL mutants. The compds. of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, e.g. imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compds. capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

```
IT 862555-81-5 862555-87-1 862556-93-2 862556-96-5 862556-99-8 862557-05-9 862557-17-3 862557-20-8 862557-23-1 862557-28-6 862557-30-0 862557-32-2 862557-34-4 862557-39-9 862557-41-3 862557-43-5 862557-54-8 862557-55-9 862557-55-3 862557-61-7 862557-64-0 862557-83-3 862557-86-6 862557-88-8 862557-92-4 862557-88-8 862557-92-4 862558-27-8 862558-40-5 862558-44-9 862558-48-3 862558-50-7
```

862559-05-5 862559-07-7 862559-08-8
862559-17-9 862559-20-4 862559-21-5
862559-30-6 862559-32-8 862559-34-0
862559-59-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(thienopyrazole derivative ABL kinase inhibitors for treatment of resistant tumors, and screening method)
RN 862555-81-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862555-87-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862556-93-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862556-96-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)(CA INDEX NAME)

RN 862556-99-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

RN 862557-05-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino](CA INDEX NAME)

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \text{C} \\ \text{NH} \end{array} \\ \begin{array}{c} \text{S} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{NH} \\ \end{array} \\ \begin{array}{c} \text{NH} \\ \end{array} \\ \begin{array}{c} \text{NH} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{NH} \\$$

RN 862557-17-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino](CA INDEX NAME)

RN 862557-20-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA
INDEX NAME)

RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-(CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me - C - NH - C \\ Me \end{array}$$

RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-41-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} & \text{O} & \text{S} & \text{H} \\ \hline & \text{C} & \text{NH} & \text{C} & \text{S} & \text{H} \\ & \text{NH} & \text{C} & \text{CH}_2 & \text{N} \\ \end{array}$$

RN 862557-43-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-54-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-55-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-58-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\$$

RN 862557-61-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-64-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

RN 862557-75-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-79-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(dimethylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-(CA INDEX NAME)

RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} & \text{O} & \text{S} & \text{H} \\ & \text{C} & \text{NH} & \text{C} & \text{S} & \text{H} \\ & \text{Me} & & \text{NH} & \text{C} & \text{CH}_2 & \text{N} \\ \end{array}$$

RN 862558-27-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\$$

RN 862558-40-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & &$$

RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} F & \text{Me} & \text{O} \\ \hline C & \text{NH} & \text{C} \\ \hline \end{array}$$

RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\$$

RN 862559-05-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-07-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & &$$

RN 862559-08-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-17-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-20-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-21-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

$$\begin{array}{c|c} F & \text{Me} \\ \hline \\ C & \text{NH} \\ \hline \end{array} \\ \begin{array}{c} C \\ \end{array} \\ \begin{array}{c} S \\ \end{array} \\ \begin{array}{c} H \\ N \\ \end{array} \\ \begin{array}{c} N \\ N \\ \end{array} \\ \begin{array}{c} O \\ \end{array} \\ \\ \begin{array}{c} O \\ \end{array} \\ \begin{array}{c$$

RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-59-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

L3 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:85753 CAPLUS Full-text

DOCUMENT NUMBER: 146:184454

TITLE: Preparation of 1H-thieno[2,3-c]pyrazoles as kinase,

particularly Aurora kinases and IGF-1R inhibitors for

treating cancer

INVENTOR(S): Fancelli, Daniele; Moll, Juergen; Pulici, Maurizio;

Quartieri, Francesca; Bandiera, Tiziano

PATENT ASSIGNEE(S): Nerviano Medical Sciences S.r.l., Italy

SOURCE: PCT Int. Appl., 69pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	TENT :	NO.			KIND		DATE		-	APPL	ICAT	DATE							
WO	2007	0098	98		A1	_	2007	0125	,	WO 2	006-:	EP64	055		2	0060	710		
	W: AE, AG, AL,				ΑM,	ΑT,	ΑU,	AΖ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,		
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,		
		GE,	GH,	GM,	HN,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	ΚM,	KN,	KP,		
		KR,	KΖ,	LA,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,		
		MW,	MX,	MZ,	NA,	NG,	NI,	NO,	NΖ,	OM,	PG,	PH,	PL,	PT,	RO,	RS,	RU,		
		SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,		
		US,	UZ,	VC,	VN,	ZA,	ZM,	ZW											
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	ΙT,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,		
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,	GH,		
		GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	KΖ,	MD,	RU,	ΤJ,	TM												
EP	1904	503			A1		2008	0402		EP 2	006-	7641.	20060710						
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	ΙE,		
		IS,	ΙT,	LI,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR			
PRIORIT	PRIORITY APPLN. INFO.:									EP 2	005-	1066	02		A 20050719				
			WO 2006-EP64055							055	W 20060710								
OTHER S							MARPAT 146:184454												

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [A = hetero/aryl on which the substituent -NHZR5 is at the ortho position to the CONH linker; R1, R2 = independently H, alkyl, CONH2, etc.; or R1CR2 = cycloalkyl; R3 = H, halo, OH, CN, alkyl, di/alkylamino, alkoxy; R4 = H, halo, alkoxy, azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, etc.; Z = a bond, CO, C(:O)NH; R5 = H, (un)substituted cycloalkyl, alk(en)yl, aryl, etc.; and their isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts] were prepared as protein kinase, especially Aurora kinases and IGF-1R, inhibitors. I, and their pharmaceutical compns., are useful in the treatment of diseases caused by and/or associated with a dysregulated protein kinase, such as cancer and cell proliferation disorders. E.g., a multi-step synthesis starting from Et 4-cyano-5-(methylthio)thiophene-2-carboxylate was given for thienopyrazole II. II was tested as Aurora-2 kinase inhibitor (IC50 = 6 nM) and for its HCT-116 colon cancer cell antiproliferative effect (IC50 = 7 nM).
- IT 921768-48-1P, 3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-49-2P, 3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]1H-thieno[2,3-c]pyrazole-5-carboxylic acid
 [1-(2-fluorophenyl)-1-methylethyl]amide 921768-50-5P,
 3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
 921768-51-6P, 3-[2-[[(Tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid

(1-methyl-1-phenylethyl) amide 921768-52-7P,

```
3-[2-[(5-Methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-53-8P, 3-[2-[[(Furan-2-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-54-9F, 3-[2-[[(Furan-3-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-55-0P, 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-
v1)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921768-56-1P,
3-[2-(Isobutanovlamino)benzovlamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic
acid (1-methyl-1-phenylethyl)amide 921768-57-2P,
3-[2-[((2-Methyl-2H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-58-3P, 3-[2-[[(1-Methyl-1H-pyrazol-3-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921768-59-4P,
3-[2-[[(1-Methyl-1H-pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-60-7P, 3-[2-[(Thiazol-4-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-61-8P, 3-[2-[[(1H-Pyrrol-3-yl)carbonyl]amino]benzoylamino]-
1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-62-9P, 3-[2-[[(1H-Imidazol-2-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl)amide 921768-63-0P 921768-64-1P
, 3-[2-[[(1-Methyl-1H-imidazol-2-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-65-2P, 3-[2-[(Phenylacetyl)amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-66-3P, 3-[2-[[(Thien-2-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-67-4P, 3-[2-[[(Thien-3-yl)carbonyl]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-68-5P, 3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-69-6P, 3-[2-[(Tetrahydropyran-4-yl)amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-70-9P, 3-[2-(2-Fluorobenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-71-0P, 3-[2-[4-(4-Methylpiperazin-1-
yl)benzoylamino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921768-72-1P,
3-[2-[[4-[(Morpholin-4-yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-73-2P, 3-[2-[[4-[(Piperidin-1-
yl)methyl]benzoyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-
carboxylic acid (1-methyl-1-phenylethyl)amide 921768-74-3P,
3-[2-[[4-[(Pyrrolidin-1-y1)methy1]benzoy1]amino]benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-75-4P, 3-[2-(2-Methylbenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-76-5P, 3-[2-(2-Methoxybenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-77-6P, 3-[2-(4-Methylbenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-78-7P, 3-[2-(4-Methoxybenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-79-8P, 3-[2-(4-Fluorobenzoylamino)benzoylamino]-1H-
thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-80-1P 921768-81-2P,
```

```
3-(2-Acetylaminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-82-3P,
3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
921768-83-4P, 3-[2-[[(Tetrahydropyran-4-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-84-5P,
3-[2-[[(Furan-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-
carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
921768-85-6P, 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-86-7P
921768-87-8P, 3-[4-(4-Methylpiperazin-1-yl)-2-[[(tetrahydropyran-4-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl)amide 921768-88-9P,
3-[4-(4-Methylpiperazin-1-yl)-2-[[(5-methyl-1H-pyrazol-3-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921768-89-0P,
3-[2-[[(Furan-2-yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-
1H-thieno[2,3-c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-90-3P, 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-
yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid (1-methyl-1-phenylethyl)amide
921768-91-4P, 3-[4-(4-Methylpiperazin-1-y1)-2-[[(1H-pyrrol-2-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921768-92-5P,
3-[2-((E)-2-Cyano-3-hydroxybut-2-enoylamino)-4-(4-methylpiperazin-1-
yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-93-6P,
3-[4-(4-Methylpiperazin-1-yl)-2-[[(tetrahydropyran-4-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-94-7P,
3-[4-(4-Methylpiperazin-1-yl)-2-[[(5-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-1H-pyrazol-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3-methyl-3
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-95-8P,
3-[2-[[(Furan-2-y1)carbonyl]amino]-4-(4-methylpiperazin-1-y1)benzoylamino]-
1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-96-9P,
3-[2-[[(2-Ethy1-5-methy1-2H-pyrazo1-3-y1)carbony1]amino]-4-(4-insert formula for the second for the second formula for the second formu
methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic
acid [1-(2-fluorophenyl)-1-methylethyl]amide 921768-97-0P,
3-[4-(4-Methylpiperazin-1-yl)-2-[[(1H-pyrrol-2-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide 921768-98-1P,
3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid benzylamide 921768-99-2P,
3-[[2-[[(1H-Pyrrol-2-y1)carbonyl]amino]benzoyl]amino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid N-((R)-1-phenylethyl)amide
921769-14-4P, 3-[2-[[(5-Methylisoxazol-4-
yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
(1-methyl-1-phenylethyl) amide 921769-15-5P,
3-[2-[[(5-Methylisoxazol-4-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid [1-(2-fluorophenyl)-1-methylethyl]amide
921769-16-6P, 3-[2-[[(5-Methylisoxazol-4-yl)carbonyl]amino]-4-(4-
methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic
acid (1-methyl-1-phenylethyl)amide 921769-17-7P,
3-[2-[[(5-Methylisoxazol-4-yl)carbonyl]amino]-4-(4-methylpiperazin-1-
yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid
[1-(2-fluorophenyl)-1-methylethyl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
```

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

RN 921768-48-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-49-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

RN 921768-50-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

Double bond geometry as shown.

$$\begin{array}{c} \text{Me} & \text{Ph} \\ \text{Me} & \text{N} \\ \text{H} \\ \text{H} & \text{N} \\ \text{H} & \text{N} \\ \text{H} & \text{N} \\ \text{H} \\ \text{H} & \text{N} \\ \text{H} & \text{N} \\ \text{H} \\ \text{H} & \text{N} \\ \text{H} \\ \text{H} & \text{H} \\ \text{H} & \text{N} \\ \text{H} \\ \text{H} & \text{N} \\ \text{H} \\ \text{H} \\ \text{H} & \text{H} \\ \text{H} \\ \text{H} & \text{H} \\ \text{H} \\ \text{H} \\ \text{H} \\ \text{H} & \text{H} \\ \text{H} \\$$

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-52-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-53-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)(CA INDEX NAME)

RN 921768-54-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(3-furanylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)(CA INDEX NAME)

RN 921768-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-56-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-methyl-1-oxopropyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-57-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-58-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-59-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-60-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(4-thiazolylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-61-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[(1H-pyrrol-3-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me - C - NH - C \\ Me \end{array}$$

RN 921768-62-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(1H-imidazol-2-ylcarbonyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-63-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-(benzoylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-64-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-methyl-1H-imidazol-2-yl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-65-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(2-phenylacetyl)amino]benzoyl]amino]-(CA INDEX NAME)

RN 921768-66-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(2-thienylcarbonyl)amino]benzoyl]amino]-(CA INDEX NAME)

RN 921768-67-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(3-thienylcarbonyl)amino]benzoyl]amino]-(CA INDEX NAME)

RN 921768-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-(acetylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-69-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[2-[(tetrahydro-2H-pyran-4-yl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-70-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)(CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me - C - NH - C \\ Me \end{array}$$

RN 921768-71-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me \\ \hline \\ Me \\ \end{array} \\ NH \\ \hline \\ C \\ NH \\ \\ NH \\ C \\ NH \\ \\ NH \\ N$$

RN 921768-72-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(4morpholinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-73-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-piperidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-74-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[2-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-75-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[(2-methylbenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)(CA INDEX NAME)

RN 921768-76-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me - C - NH - C \\ Me \end{array} \qquad \begin{array}{c} S \\ \hline \\ Me \end{array} \qquad \begin{array}{c} H \\ N \\ \hline \\ NH - C \\ \hline \\ OMe \end{array} \qquad \begin{array}{c} C - NH \\ \hline \\ OMe \end{array}$$

RN 921768-77-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-methylbenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-(CA INDEX NAME)

RN 921768-78-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-methoxybenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-79-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(4-fluorobenzoyl)amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-(CA INDEX NAME)

RN 921768-80-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 921768-81-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-(acetylamino)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 921768-82-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]benzoyl]amino]-N[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.

RN 921768-83-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
 N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-84-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c}
F & Me \\
\hline
C & NH & C \\
\hline
Me & NH & C \\
\hline
NH & C \\
NH & C \\
\hline
NH & C \\
NH & C \\
NH & C \\
\hline
NH & C \\
N$$

RN 921768-85-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 921768-86-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)-, hydrochloride (1:?) (CA INDEX NAME)

Double bond geometry as shown.

RN 921768-87-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-88-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-89-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-90-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921768-91-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-92-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(2E)-2-cyano-3-hydroxy-1-oxo-2-buten-1-yl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

Double bond geometry as shown.

RN 921768-93-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-94-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-95-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

 $\begin{tabular}{ll} N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME) \\ \end{tabular}$

RN 921768-96-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 921768-97-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-98-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(phenylmethyl)-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]- (CA INDEX NAME)

RN 921768-99-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-phenylethyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-(CA INDEX NAME)

Absolute stereochemistry.

RN 921769-14-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921769-15-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

 $\begin{tabular}{ll} N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]- (CA INDEX NAME) \\ \end{tabular}$

RN 921769-16-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 921769-17-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[2-[[(5-methyl-4isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA
INDEX NAME)

```
carboxylate 862559-62-4P 921767-86-4P
921767-87-5P 921767-88-6P 921767-89-7P
921767-90-0P, 3-(2-Aminobenzoylamino)-1H-thieno[2,3-c]pyrazole-5-
carboxylic acid tert-butyl ester 921767-91-1P,
3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid tert-butyl ester 921767-92-2P
921767-93-3P 921767-94-4P 921767-95-5P
921767-96-6P 921767-97-7P 921767-98-8P
921767-99-9P 921768-00-5P 921768-01-6P
921768-02-7P 921768-03-8P 921768-04-9P,
3-[2-[[(1H-Pyrrol-2-yl)carbonyl]amino]benzoylamino]-1H-thieno[2,3-
c]pyrazole-5-carboxylic acid tert-butyl ester 921768-05-0P
921768-06-1P 921768-07-2P 921768-08-3P
921768-09-4P 921768-10-7P 921768-11-8P
921768-12-9P 921768-13-0P 921768-14-1P
921768-15-2P 921768-16-3P 921768-17-4P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-[[(1H-pyrrol-2-methyl-1-phenylethyl)carbamoyl]]
yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-18-5P,
3-[2-[(5-Methylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethylisoxazol-4-yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-wethyl-1-
phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921768-19-6P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-
[[(tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-
1-carboxylic acid ethyl ester 921768-20-9P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[2-[[(5-methyl-1H-pyrazol-3-
yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-21-0P,
3-[2-[(Furan-2-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino]-5-[(1-methy1-1-y1)carbony1]amino]benzoylamino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino[(1-methy1-1-y1)carbony1]amino
phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921768-23-2P, 3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-
yl)carbonyl]amino]benzoylamino]-5-[(1-methyl-1-
phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921768-25-4P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-
methylpiperazin-1-yl)-2-[[(1H-pyrrol-2-
yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-27-6P,
3-[2-[[(5-Methylisoxazol-4-yl)carbonyl]amino]-4-(4-methylpiperazin-1-
yl)benzoylamino]-5-[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-29-8P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-
[[(tetrahydropyran-4-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-
1-carboxylic acid ethyl ester 921768-31-2P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-methylpiperazin-1-yl)-2-[[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperazin-1-yl)-2-[(5-yl)methylpiperaz
methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921768-33-4P,
3-[2-[[(Furan-2-y1)carbony1]amino]-4-(4-methylpiperazin-1-y1)benzoylamino]-
5-[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic
acid ethyl ester 921768-35-6P,
3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]-4-(4-insert formula for the second second
methylpiperazin-1-yl)benzoylamino]-5-[(1-methyl-1-
phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921768-36-7P, 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-
[2-[[(1H-pyrrol-2-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921768-37-8P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1-(methylisoxazol-1
4-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-38-9P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[(tetrahydropyran-
4-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-39-0P,
```

```
5-[[1-(2-Fluoropheny1)-1-(methyl)ethyl]carbamoy1]-3-[2-[[(5-methyl-1H-1)ethyl-1H-1]ethyl-1H-1]ethyl-1H-1
pyrazol-3-yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921768-40-3P,
5-[[1-(2-Fluoropheny1)-1-(methy1)ethy1]carbamoy1]-3-[2-[[(furan-2-interpretation of the context of the contex
yl)carbonyl]amino]benzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921768-41-4P,
3-[2-[[(2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]benzoylamino]-5-
[[1-(2-fluorophenyl)-1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921768-42-5P,
5-[[1-(2-Fluorophenyl)-1-(methyl)] ethyl]carbamoyl]-3-[4-(4-methyl)piperazin-
1-yl)-2-[[(1H-pyrrol-2-yl)carbonyl]amino]benzoylamino]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-43-6P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[2-[[(5-methylisoxazol-
4-y1)carbonyl]amino]-4-(4-methylpiperazin-1-y1)benzoylamino]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-44-7P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-
1-y1)-2-[[(tetrahydropyran-4-y1)carbonyl]amino]benzoylamino]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-45-8P,
5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-[4-(4-methylpiperazin-
1-y1)-2-[[(5-methyl-1H-pyrazol-3-y1)carbonyl]amino]benzoylamino]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-46-9P,
5-[[1-(2-Fluoropheny1)-1-(methy1)ethy1]carbamoy1]-3-[2-[[(furan-2-interpretation of the contemps of the cont
yl)carbonyl]amino]-4-(4-methylpiperazin-1-yl)benzoylamino]thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921768-47-0P,
3-[2-[((2-Ethyl-5-methyl-2H-pyrazol-3-yl)carbonyl]amino]-4-(4-
methylpiperazin-1-yl)benzoylamino]-5-[[1-(2-fluorophenyl)-1-
methylethyl]carbamovl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921769-00-8P 921769-02-0P 921769-03-1P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-(2-nitrobenzoylamino)thieno[2,3-
c]pyrazole-1-carboxylic acid ethyl ester 921769-04-2P,
5-[[1-(2-Fluorophenyl)-1-methylethyl]carbamoyl]-3-(2-
nitrobenzoylamino)thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921769-05-3P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-(4-
methylpiperazin-1-yl)-2-nitrobenzoylamino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921769-06-4P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[[2-nitro-4-[(pyrrolidin-1-
yl)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl
ester 921.769-0.7-5P, 5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[[2-phenylethyl)carbamoyl]-3-[[2-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoyl]-3-[[3-phenylethyl]carbamoylethyl]carbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylethyllcarbamoylet
nitro-4-[(piperidin-1-yl)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921769-08-6P,
5-[(1-Methyl-1-phenylethyl)carbamoyl]-3-[4-[(morpholin-4-yl)methyl]-2-
nitrobenzoylamino]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921769-09-7P, 5-[[1-(2-Fluorophenyl)-1-(methyl)ethyl]carbamoyl]-3-
[4-(4-methylpiperazin-1-yl)-2-nitrobenzoylamino]thieno[2,3-c]pyrazole-1-
carboxylic acid ethyl ester 921769-10-0P,
3-(2-Aminobenzoylamino)-5-[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl)carbamoyl]thieno[2,3-methyl-1-phenylethyl]
c]pyrazole-1-carboxylic acid ethyl ester 921769-11-1P,
3-(2-Aminobenzoylamino)-5-[[1-(2-fluorophenyl)-1-
methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl ester
921769-12-2P, 3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-5-
[(1-methyl-1-phenylethyl)carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid
ethyl ester 921769-13-3P,
3-[2-Amino-4-(4-methylpiperazin-1-yl)benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]benzoylamino]-5-[1-(2-fluorophenyl)-1-yl]ben
1-methylethyl]carbamoyl]thieno[2,3-c]pyrazole-1-carboxylic acid ethyl
ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
          (intermediate; preparation of thienopyrazoles as kinase inhibitors for
          treating cancer)
```

RN

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 862559-62-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-86-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-nitrobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-87-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-88-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-aminobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-89-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-90-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(2-aminobenzoyl)amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 921767-91-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 921767-92-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-93-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-94-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-95-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-96-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-97-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921767-98-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CAINDEX NAME)

RN 921767-99-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA

RN 921768-00-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921768-01-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921768-02-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921768-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 921768-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 921768-05-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-06-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-07-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-08-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-09-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-10-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-11-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-12-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-13-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-14-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-15-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-16-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921768-17-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-18-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-19-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-20-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-21-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-23-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-25-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-27-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-29-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-31-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-33-4 CAPLUS

CN

1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-35-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-36-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-37-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-38-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-39-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-40-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[(2-furanylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-41-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921768-42-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[(1H-pyrrol-2-ylcarbonyl)amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-43-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,

5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[[(5-methyl-4-isoxazolyl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-44-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(tetrahydro-2H-pyran-4-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-45-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-[[(5-methyl-1H-pyrazol-3-yl)carbonyl]amino]benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-46-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[2-[(2-furanylcarbonyl)amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921768-47-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-[[(1-ethyl-3-methyl-1H-pyrazol-5-yl)carbonyl]amino]-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921769-00-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[(2-nitrobenzoyl)amino]-, 1-ethyl ester (CA INDEX NAME)

RN 921769-02-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, 1-ethyl ester
2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 921769-01-9 CMF C21 H22 N6 O7 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 921769-03-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-nitrobenzoyl)amino]-, ethyl ester (CA INDEX NAME)

RN 921769-04-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-nitrobenzoyl)amino]-, ethyl ester (CA INDEX NAME)

RN 921769-05-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921769-06-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-nitro-4-(1-pyrrolidinylmethyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921769-07-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[2-nitro-4-(1-piperidinylmethyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921769-08-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4-morpholinylmethyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921769-09-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)-2-nitrobenzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 921769-10-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-aminobenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921769-11-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-aminobenzoyl)amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921769-12-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 921769-13-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[2-amino-4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:916512 CAPLUS <u>Full-text</u> DOCUMENT NUMBER: 145:314984

TITLE: Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, their

preparation, compositions containing them and their

use as inhibitors of protein kinases

INVENTOR(S): Barberis, Claude; Carry, Jean-Christophe; Doerflinger,

Gilles; Barbalat-Damour, Dominique; Clerc,

Francois-Frederic; Minoux, Herve

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr. SOURCE: PCT Int. Appl., 138pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA:									APPLICATION NO.					DATE				
WO									WO 2006-FR480					20060303				
	W:			AL,	AM,	AT, AU,		AZ,	BA,	ВВ	, BG,	BR,	BW,	BY,	BZ,	CA,	CH,	
											, EC,							
											, JP,							
											, MA,							
											, PL,							
		SG,	SK,	SL,	SM,	SY,	ТJ,	TM,	TN,	TR	, TT,	TZ,	UA,	UG,	US,	UZ,	VC,	
		VN,	YU,	ZA,	ZM,	ZW												
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE	, ES,	FI,	FR,	GB,	GR,	HU,	ΙE,	
		IS,	ΙΤ,	LT,	LU,	LV,	MC,	NL,	PL,	PT	, RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	
		CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML	, MR,	NE,	SN,	TD,	ΤG,	BW,	GH,	
		GM,	ΚE,	LS,	MW,	${ m MZ}$,	NA,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
		KG,	KΖ,	MD,	RU,	ΤJ,	TM											
FR	2882	751				A1 20060908 FR 2005-2199							20050304					
	2882	B1 20070914																
	AU 2006219805													20060303				
									CA 2006-2599270									
EP					A1 20071128				EP 2006-726018									
	R:	•	•	,		,			,		, ES,	•	•	,	•	•	,	
						LU,	LV,	MC,	NL,	PL	, PT,	RO,	SE,	SI,	SK,	TR,	AL,	
	BA, HR, MK,																	
	JP 2008531663									JP 2007-557544								
	US 20080146542							US 2007-846669										
					А					MX 2007-10753					20070903			
	KR 2007113214								KR 2007-720106									
	IN 2007KN03327																	
				А	20080326			CN 2006-80010837 FR 2005-2199										
IORITY APPLN. INFO.:																		
											2006-1				W 2	0060	303	
HER SO	DURCE	(S):			CASI	REAC	T 14	5 : 31	4984	; M	ARPAT	145	:314	984				

AΒ Title compds. I [R1 = independently NHCOR2, NHCONHR2, NHCOOR2; R2 = H, (un) substituted cyclo/alkyl, hetero/aryl, etc.; R3-R5 = independently H, (un) substituted alkyl, alkyl/aryl, alkyl/heteroaryl; or NR3R4 = (un) substituted heterocyclyl; etc.] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II. II inhibited Aurora 1, Aurora 2, CDK2 and Tie2 with IC50 of 8 nM, 8 nM, 177 nM, and 117 nM, resp. I are useful for treating neoplasm, psoriasis, glaucoma, leukemias, inflammations, etc. 909252-57-9P, N-[5-(2-Phenylhydrazinocarbonyl)-1H-thieno[2,3-ΙT c]pyrazol-3-yl]-4-methoxybenzamide 909252-61-5P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-62-6P, N-[5-(2-Cyclohexylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4methoxybenzamide 909252-63-7P, N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-64-8P, N-[5-[2-(2-Ethylphenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-65-9P, N-[5-[[2-(2-Fluorophenyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-methoxybenzamide 909252-66-0P, 4-Methoxy-N-[5-[[2-(2-methylphenyl)hydrazino]carbonyl]-1H-thieno[2,3c]pyrazol-3-yl]benzamide 909252-67-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(morpholin-4-yl)methyl]benzamide 909252-73-9P, 4-Bromo-N-[5-[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3c]pyrazol-3-yl]benzamide 909252-75-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-78-4P, cis-4-[(3,5-Dimethylpiperazin-1-yl)methyl]-N-[5-[(2-methyl-2-metphenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide 909252-79-5P 909252-89-7P 909252-90-0P 909252-91-1P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1Hthieno[2,3-c]pyrazol-3-yl]-4-[(piperazin-1-yl)methyl]benzamide 909252-92-2P 909252-93-3P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-[(3-methylpiperazin-1-yl)methyl]benzamide 909252-94-4P 909252-96-6P 909252-97-7P 909252-98-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-

3-[(4-methylpiperazin-1-yl)methyl]benzamide 909252-99-9P

```
909253-03-8P, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-
thieno[2,3-c]pyrazol-3-yl]-4-[(piperidin-1-yl)methyl]benzamide
909253-04-9P 909253-05-0P,
N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-
4-[(pyrrolidin-1-yl)methyl]benzamide 909253-06-1P
909253-07-2P, 4-[(Azetidin-1-y1)methy1]-N-[5-[(2-methy1-2-y1)methy1]]
phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
909253-08-3P, 4-[[(2-Dimethylaminoethyl) (methyl) amino]methyl]-N-[5-
[(2-methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-
vl]benzamide 909253-09-4P 909253-10-7P
909253-11-8P 909253-12-9P,
N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-
3-[(morpholin-4-yl)methyl]benzamide 909253-13-0P
909253-16-3P, 4-[[(2-Diethylaminoethyl)amino]methyl]-N-[5-[(2-
methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
909253-17-4P 909253-18-5P,
4-[[Methyl(phenyl)amino]methyl]-N-[5-[(2-methyl-2-
phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
909253-20-9P, 4-[(Diisopropylamino)methyl]-N-[5-[(2-methyl-2-
phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
trifluoroacetate 909253-21-0P,
N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-
methoxybenzamide 909253-22-1P,
4-Methoxy-N-[5-[[2-(pyridin-2-yl))hydrazino]carbonyl]-1H-thieno[2,3-
c]pyrazol-3-yl]benzamide 909253-23-2P 909253-28-7P,
N-(2-Methoxymethylpyrrolidin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)-3-[4-(4-methylpiperazin-1-yl)
yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide
909253-30-1P, N-[5-[(2-Benzyl-2-methylhydrazino)carbonyl]-1H-
thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
909253-32-3P, N-(Piperidin-1-yl)-3-[4-(4-methylpiperazin-1-
yl)benzoylamino]-1H-thieno[2,3-c]pyrazole-5-carboxamide
909253-34-5P, N-[5-(2-Benzylhydrazinocarbonyl)-1H-thieno[2,3-
c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-36-7P
, N-[5-[(2-Ethyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-
4-(4-methylpiperazin-1-yl)benzamide 909253-38-9P,
N-[5-[(2-Benzyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-
4-(4-methylpiperazin-1-yl)benzamide 909253-40-3P,
N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-
4-(4-methylpiperazin-1-yl)benzamide 909253-46-9P,
N-[5-[2-(4-Chlorophenyl)-2-cyclobutylmethylhydrazino]carbonyl]-1H-
thieno[2,3-c]pyrazo[3-y1]-4-(4-methylpiperazin-1-y1) benzamide
909253-52-7P, N-[5-[[2-Ethyl-2-(4-fluorophenyl)hydrazino]carbonyl]-
1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-methylpiperazin-1-yl)benzamide
909253-55-0P, N-[5-[[2-(4-Fluorophenyl)-2-(2-
methoxyethyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4-
methylpiperazin-1-yl)benzamide 909253-58-3P,
N-[5-[2-Ethyl-2-(o-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-
yl]-4-(4-methylpiperazin-1-yl)benzamide 909253-59-4P,
N-[5-[2-Ethyl-2-(m-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-
y1]-4-(4-methylpiperazin-1-y1) benzamide 909253-60-7P,
N-[5-[2-(4-Fluoropheny1)-2-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonyl]-1H-thieno[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino]carbonylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobutylhydrazino[2,3-isobuty
c]pyrazol-3-y1]-4-(4-methylpiperazin-1-y1)benzamide 909253-63-0P
909253-67-4P, 6-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-2-yl)-N-[5-[(2-methyl-
phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]nicotinamide
909253-68-5P, N-[5-(Benzylidenehydrazinocarbonyl)-1H-thieno[2,3-
c]pyrazol-3-y1]-4-(4-methylpiperazin-1-y1)benzamide 909253-71-0P
, N-[5-[(2-Methyl-2-phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-
y1]-4-[2-(morpholin-4-y1)] ethoxy] benzamide 909253-74-3P,
4-(4-Methyl-[1,4]diazepan-1-yl)-N-[5-[(2-methyl-2-
phenylhydrazino)carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]benzamide
```

909253-75-4P 909253-76-5P 909253-77-6P,

N-[5-[2-Ethyl-2-(p-tolyl)hydrazino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-

yl]-4-(4-methylpiperazin-1-yl)benzamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

909252-57-9 CAPLUS RN

1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, CN 2-phenylhydrazide (CA INDEX NAME)

RN 909252-61-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

$$Me = NH - C$$

$$M = NH - C$$

$$M$$

909252-62-6 CAPLUS RN

1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, CN 2-cyclohexylhydrazide (CA INDEX NAME)

909252-63-7 CAPLUS

1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, CN 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)

$$\mathsf{Ph} = \mathsf{CH}_2 = \overset{\mathsf{Ph}}{\mathsf{N}} = \mathsf{NH} = \overset{\mathsf{O}}{\mathsf{C}} = \overset{\mathsf{H}}{\mathsf{NH}} = \overset{\mathsf{O}}{\mathsf{NH}} = \overset{\mathsf{OM}}{\mathsf{NH}} = \overset{\mathsf{OM}$$

RN 909252-64-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-ethylphenyl)hydrazide (CA INDEX NAME)

RN 909252-65-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-fluorophenyl)hydrazide (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

RN 909252-66-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-methylphenyl)hydrazide (CA INDEX NAME)

RN 909252-67-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-73-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-bromobenzoyl)amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-75-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-78-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.

RN 909252-79-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]benzoyl]amino]-,
2-(4-chlorophenyl)-2-methylhydrazide, rel- (CA INDEX NAME)

Relative stereochemistry.

>Me

RN 909252-89-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-90-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

PAGE 1-A

N=NH-C

N=NH

PAGE 1-B

RN 909252-91-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperazinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-92-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperazinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909252-93-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-94-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(3-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

−Me

RN 909252-96-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(diethylamino)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide, trifluoroacetate (9CI) (CA INDEX NAME)

CM 1

CRN 909252-95-5 CMF C25 H28 N6 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 909252-97-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(diethylamino)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909252-98-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-99-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

PAGE 1-B

___Me

RN 909253-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-04-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-piperidinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-05-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-06-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-07-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-08-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-09-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

C1 Me O S N N O CH2 N CH2

PAGE 1-B

___CH2__NMe2

RN 909253-10-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

$$\begin{array}{c} Ph \\ Me-N-NH-C \\ \hline \end{array} \\ \begin{array}{c} S \\ \hline \end{array} \\ \begin{array}{c} H \\ N \\ \hline \end{array} \\ NH-C \\ \end{array} \\ \begin{array}{c} CH2-N \\ \hline \end{array} \\ \begin{array}{c} CH2-N \\ \hline \end{array} \\ \end{array}$$

RN 909253-11-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[(tetrahydro-1,4-oxazepin-4(5H)-yl)methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-12-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-13-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-16-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

$$\begin{array}{c} \text{Ph} \\ \text{Me} = \overset{\text{Ph}}{\text{N}} = \overset{\text{O}}{\text{N}} = \overset{\text{O}}{\text{N}} = \overset{\text{CH}_2}{\text{N}} = \overset{\text{CH}_2}{\text{N}}$$

RN 909253-17-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[[2-(diethylamino)ethyl]amino]methyl]benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

___CH2__NEt2

RN 909253-18-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-[(methylphenylamino)methyl]benzoyl]amino]-,
2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-20-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-, 2-methyl-2-phenylhydrazide, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 909253-19-6 CMF C27 H32 N6 O2 S

CM 2

CRN 76-05-1 CMF C2 H F3 O2

RN 909253-21-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(phenylmethyl)hydrazide (CA INDEX NAME)

RN 909253-22-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-, 2-(2-pyridinyl)hydrazide (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 909253-23-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-28-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[2-(methoxymethyl)-1-pyrrolidinyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c} \text{MeO-CH2} \\ \text{N-NH-} \\ \text{$$

RN 909253-30-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)

$$Ph-CH_2-N-NH-C$$

$$S$$

$$N$$

$$N$$

$$NH-C$$

$$N$$

$$N$$

$$N$$

RN 909253-32-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-1-piperidinyl- (CA INDEX NAME)

RN 909253-34-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethyl)hydrazide (CA INDEX NAME)

$$\mathsf{Ph}\mathsf{-CH}_2\mathsf{-NH}\mathsf{-NH}\mathsf{-}\overset{\overset{\circ}{\mathsf{U}}}{\overset{\circ}{\mathsf{U}}}\mathsf{-}\overset{\mathsf{S}}{\mathsf{N}}\mathsf{-}\overset{\mathsf{H}}{\mathsf{N}}\mathsf{-}\overset{\mathsf{N}}{\mathsf{N}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{U}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{N}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{N}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}}\mathsf{-}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{-}}\overset{\mathsf{U}}{\mathsf{$$

RN 909253-36-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-38-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)

RN 909253-40-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-46-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide (CA INDEX NAME)

$$\begin{array}{c} C1 \\ \hline \\ N-NH-C \\ \hline \\ CH2 \\ \end{array}$$

RN 909253-52-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-fluorophenyl)hydrazide (CA INDEX NAME)

RN 909253-55-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-fluorophenyl)-2-(2-methoxyethyl)hydrazide (CA INDEX NAME)

RN 909253-58-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(2-methylphenyl)hydrazide (CA INDEX NAME)

$$\underbrace{ \begin{bmatrix} \mathsf{E}^{\mathsf{t}} \\ \mathsf{N} \\ \mathsf{M} \mathsf{e} \end{bmatrix}}_{\mathsf{M} \mathsf{e}} \underbrace{ \begin{bmatrix} \mathsf{S} \\ \mathsf{N} \\ \mathsf{N} \end{bmatrix}}_{\mathsf{N} \mathsf{H}} \underbrace{ \begin{bmatrix} \mathsf{N} \\ \mathsf{C} \end{bmatrix}}_{\mathsf{N} \mathsf{H}} \underbrace{ \begin{bmatrix} \mathsf{N} \\ \mathsf{N} \end{bmatrix}}_{\mathsf{N} \mathsf{H}} \underbrace$$

RN 909253-59-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(3-methylphenyl)hydrazide (CA INDEX NAME)

RN 909253-60-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-fluorophenyl)-2-(2-methylpropyl)hydrazide (CA INDEX NAME)

RN 909253-63-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(3-bromophenyl)-2-ethylhydrazide (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 909253-67-4 CAPLUS

CN

1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[[6-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)-3pyridinyl]carbonyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-68-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethylene)hydrazide (CA INDEX NAME)

RN 909253-71-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-[2-(4-morpholinyl)ethoxy]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-74-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-75-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide, 2,2,2-trifluoroacetate
(1:1) (CA INDEX NAME)

CM 1

CRN 909253-46-9
CMF C29 H32 C1 N7 O2 S

CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 909253-76-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-(4-fluorophenyl)hydrazide, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 909253-52-7
CMF C26 H28 F N7 O2 S

CM 2

CRN 76-05-1

CMF C2 H F3 O2

RN 909253-77-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-,
2-ethyl-2-(4-methylphenyl)hydrazide (CA INDEX NAME)

909252-58-0P, 1-(1-Ethoxyethyl)-3-(4-methoxybenzoylamino)-1Hthieno[2,3-c]pyrazole-5-carboxylic acid 909252-59-1P 909252-60-4 \mathbb{P} , Ethyl 1-(1-ethoxyethyl)-3-(4-methoxybenzoylamino)-1Hthieno[2,3-c]pyrazole-5-carboxylate 909252-68-2P 909252-69-3P, tert-Butyl 3-amino-5-[(2-methyl-2phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-70-6P, N'-Methyl-N'-phenyl-3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylic hydrazide 909252-71-7P, Ethyl 3-amino-1H-thieno[2,3-c]pyrazole-5-carboxylate 909252-74-0P, tert-Butyl 3-(4-bromobenzoylamino)-5-[(2-methyl-2phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-76-2P, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[4-[(4-methylpiperazin-1-yl)methyl]benzoylamino]thieno[2,3-c]pyrazole-1carboxylate 909252-80-8P, tert-Butyl 3-(4-chloromethylbenzoylamino)-5-[(2-methyl-2phenylhydrazino)carbonyl]thieno[2,3-c]pyrazole-1-carboxylate 909252-81-9P 909252-82-0P 909253-00-5P, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[3-[(4methylpiperazin-1-yl)methyl]benzoylamino]thieno[2,3-c]pyrazole-1carboxylate 909253-01-6P 909253-14-1P, tert-Butyl 5-[(2-methyl-2-phenylhydrazino)carbonyl]-3-[[3-[(morpholin-4y1)methyl]benzoyl]amino]thieno[2,3-c]pyrazole-1-carboxylate

909253-15-2P 909253-24-3P, Ethyl 1-(1-ethoxyethyl)-3-[4-(4-methylpiperazin-1-yl)benzoylamino]-1H-thieno[2,3c]pyrazole-5-carboxylate 909253-25-4P 909253-29-8P 909253-31-2P 909253-33-4P 909253-35-6P 909253-37-8P 909253-43-6P 909253-48-1P 909253-53-8P 909253-69-6P, N-[5-(Hydrazinocarbonyl)-1H-thieno[2,3-c]pyrazol-3-yl]-4-(4methylpiperazin-1-yl)benzamide 909253-72-1P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (intermediate; preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases) RN 909252-58-0 CAPLUS 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, CM1-(1-ethoxyethyl)-3-[(4-methoxybenzoyl)amino]- (CA INDEX NAME)

RN 909252-59-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-(1-ethoxyethyl)-3-[(4-methoxybenzoyl)amino]-, 2-phenylhydrazide (CA INDEX NAME)

RN 909252-68-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909252-69-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909252-70-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909252-71-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, ethyl ester (CA INDEX NAME)

RN 909252-74-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(4-bromobenzoyl)amino]-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909252-76-2 CAPLUS

IN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909252-80-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(chloromethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909252-81-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(chloromethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)

RN 909252-82-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)

RN 909253-00-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,
3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-,
1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909253-01-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[3-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)

PAGE 1-B

__Me

RN 909253-14-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-(2-methyl-2-phenylhydrazide) (CA INDEX NAME)

RN 909253-15-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[3-(4-morpholinylmethyl)benzoyl]amino]-, 1-(1,1-dimethylethyl) ester, 5-[2-(4-chlorophenyl)-2-methylhydrazide] (CA INDEX NAME)

RN 909253-24-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 909253-25-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)

RN 909253-29-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 1-(1-ethoxyethyl)-N-[2-(methoxymethyl)-1-pyrrolidinyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 909253-31-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)

RN 909253-33-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-1-piperidinyl- (CA INDEX NAME)

RN 909253-35-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(phenylmethyl)hydrazide (CA INDEX NAME)

RN 909253-37-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-43-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

RN 909253-48-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-(4-chlorophenyl)-2-(cyclobutylmethyl)hydrazide (CA INDEX NAME)

RN 909253-53-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-ethyl-2-(4-fluorophenyl)hydrazide (CA INDEX NAME)

RN 909253-69-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, hydrazide (CA INDEX NAME)

$$H_2N-NH$$

RN 909253-72-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-[2-(4-morpholinyl)ethoxy]benzoyl]amino]-, 2-methyl-2-phenylhydrazide (CA INDEX NAME)

IT 909253-39-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909253-39-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 2-phenyl-2-(phenylmethyl)hydrazide (CA INDEX NAME)

(preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909253-70-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

IT 909252-87-5P, N'-(4-Chlorophenyl)-N'-methyl-3-amino-1H-thieno[2,3-1]

c]pyrazole-5-carboxylic hydrazide


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of hydrazinocarbonyl-thieno[2,3-c]pyrazoles as inhibitors of protein kinases)

RN 909252-87-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-,

2-(4-chlorophenyl)-2-methylhydrazide (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:708185 CAPLUS Full-text

DOCUMENT NUMBER: 145:167237

TITLE: Preparation of heterocyclo-fused pyrazoles as protein

kinase inhibitors.

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele;

Pittala', Valeria; D' Anello, Matteo

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy SOURCE: U.S. Pat. Appl. Publ., 28 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060160874	A1	20060720	US 2005-37986	20050118
PRIORITY APPLN. INFO.:			US 2005-37986	20050118

OTHER SOURCE(S): MARPAT 145:167237

GΙ

$$\mathbb{R}^2$$
 \mathbb{R}^1
 $\mathbb{R}^{\mathbb{N}}$
 \mathbb{N}
 $\mathbb{N$

Title compds. [I; X NR', O, S, SO, SO2; R, R1 = H, (substituted) R', COR', CO2R', CONHR', SO2R', etc.; R' = H, (substituted) alkyl, alkenyl, alkynyl, aryl, heterocyclyl, aralkyl; R2 = R', CH2OR', OR'], were prepared Thus, Me 3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate (preparation from Me 5-bromo-4-nitrothiophene-2-carboxylate and morpholin-4-ylbenzoic acid given) inhibited Aurora-1 kinase with IC50 <100 nM.

IT 648412-09-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclo-fused pyrazoles as protein kinase inhibitors)

RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2006:510459 CAPLUS Full-text

DOCUMENT NUMBER: 145:8163

TITLE: Substituted 1H-thieno[2,3-c]pyrazoles, their

preparation, compositions containing them and their use as inhibitors of protein kinases for treating

cancer

INVENTOR(S): Carry, Jean-Christophe; Doerflinger, Gilles; Bigot,

Antony; Barbalat-Damour, Dominique; Clerc, Francois

PATENT ASSIGNEE(S): Aventis Pharma S.A., Fr. SOURCE: PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.																	
						WO 2005-FR2933											
	W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KN,	KP,	KR,
		KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	LY,	MA,	MD,	MG,	MK,	MN,	MW,	MX,
		MZ,	NA,	NG,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,
		SG,	SK,	SL,	SM,	SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,
		VN,	YU,	ZA,	ZM,	ZW											
	RW:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,
		IS,	ΙΤ,	LT,	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	ВJ,
		CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG,	BW,	GH,
		GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,
				,	RU,	•											
FR 2878442			A1 20060602 FR 2004-12644					20041129									
FR 2878442		B1 20081024															
							2007										
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,
					•	LU,	LV,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	AL,
			HR,														
				T 20080626 JP 2007-542047													
US 20080058402																	
PRIORITY	APP:	LN.	INFO	.:						FR 2							
										WO 2				Ī	W 2	0051	125
OTHER SOU	JRCE	(S):			CASI	REAC	T 14	5:81	63 ;	MARP.	AT 1	45 : 81	163				

$$\begin{array}{c} R^{3} \\ O-NH \\ S-M \\ N \end{array}$$

AB Title compds. I [R1 = independently R2, NHCOR2, CH:CH-R2, etc.; R2 = heteroaryl/aryl/heterocyclo/cyclo/alkyl, etc.; R3 = alkyl, alkyl/aryl, alkyl/heteroaryl; with the proviso that when R3 = alkyl, than R1 is not hetero/aryl or CH:CH-R2, where R2 = hetero/aryl; their racemates, enantiomers and diastereomers, and their pharmaceutical addition salts with mineral and organic acids or mineral and organic bases] were prepared as inhibitors of protein kinases, particularly Aurora 2 kinase (data) for treating cancer (no data). E.g., a 7-step synthesis starting from 3,4,5-tribromopyrazole was given for thienopyrazole II•HCl. II inhibited Aurora 2, CDK2 and Tie2 with IC50 of < 50 nM, < 500 nM and < 500 nM, resp.

IT 888485-00-5P, 5-[(N-Phenoxyamino)carbonyl]-3-[[(thien-2-

yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole hydrochloride 888485-03-8P, 5-[(N-Phenoxyamino)carbonyl]-3-[[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 1H-thieno[2,3-c]pyrazoles as inhibitors of protein kinases and their use for treating cancer)

RN 888485-00-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-phenoxy-3-[(2-thienylcarbonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)

HC1

RN 888485-03-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-phenoxy-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

IT 836633-22-8P, Ethyl 1-(1-ethoxyethyl)-3-[[(thien-2yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole-5-carboxylate
888485-01-6P, 1-(1-Ethoxyethyl)-5-[(N-phenoxyamino)carbonyl]-3[[(thien-2-yl)carbonyl]amino]-1H-thieno[2,3-c]pyrazole
888485-02-7P, 1-(1-Ethoxyethyl)-3-[[(thien-2-yl)carbonyl]amino]-1Hthieno[2,3-c]pyrazole-5-carboxylic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(intermediate; preparation of 1H-thieno[2,3-c]pyrazoles as inhibitors of protein kinases and their use for treating cancer)


RN 836633-22-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 1-(1-ethoxyethyl)-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 888485-01-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,


1-(1-ethoxyethyl)-N-phenoxy-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



RN 888485-02-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

1-(1-ethoxyethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:1104610 CAPLUS Full-text

DOCUMENT NUMBER: 145:249062

TITLE: Synthesis, reactions and antimicrobial activity of

2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-

carbonitrile

AUTHOR(S): Abdel-Mohsen, Shawkat A.

CORPORATE SOURCE: Chemistry Department, Faculty of Science, Assiut

University, Assiut, 71516, Egypt

SOURCE: Bulletin of the Korean Chemical Society (2005), 26(5),

719-728

CODEN: BKCSDE; ISSN: 0253-2964

PUBLISHER: Korean Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 145:249062

AB A novel 2-amino-4-(8-quinolinol-5-yl)-1-(p-tolyl)-pyrrole-3-carbonitrile (I) was obtained by the reaction of 2-[2-bromo-1-(8-hydroxyquinolin-5-yl)-ethylidene]-malononitrile with p-toluidine. The new synthon I could be annulated to the corresponding pyrrolo[2,3-d]pyrimidines, triazolo[1,5-c]pyrrolo[3,2-e]pyrimidines, pyrrolo[2,3-c]pyrazoles, pyrrolo[1,2-a]pyrrolo[3,2-e]pyrimidine and imidazo[1,2-c]pyrrolo[3,2-e]pyrimidine via the reactions with some reagents such as acetic anhydride, formamide, tri-Et orthoformate, hydrazine hydrate, hydroxylamine, ethylenediamine, carbon disulfide and phosphorus oxychloride. Chemical and spectroscopic data for the structures of these compds. were presented. The antifungal and antibacterial activity of the newly synthesized compds. were evaluated.

IT 906450-63-3P

RN

CN

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

906450-63-3 CAPLUS

8-Quinolinol, 5-[3-amino-1,6-dihydro-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-4-yl]- (CA INDEX NAME)

$$\stackrel{\text{OH}}{\longrightarrow} \stackrel{\text{NH}_2}{\longrightarrow} \stackrel{$$

IT 906450-67-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation, antifungal and antibacterial activity of (pyrrolo)pyrazoles via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-67-7 CAPLUS

CN Thiourea, N-[1,6-dihydro-4-(8-hydroxy-5-quinoliny1)-6-(4-methylphenyl)pyrrolo[2,3-c]pyrazol-3-yl]-N'-phenyl- (CA INDEX NAME)

IT 906450-64-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation, antifungal and antibacterial activity of (pyrrolo) pyrazoles

via condensation of amino(cyano)tolyl(quinolinyl)pyrrole with

hydroxylamine followed by heterocyclization with appropriate reagents)

RN 906450-64-4 CAPLUS

CN 8-Quinolinol, 5-[1,6-dihydro-6-(4-methylphenyl)-3-

[(phenylmethylene)amino]pyrrolo[2,3-c]pyrazol-4-yl]- (CA INDEX NAME)

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2005:823564 CAPLUS Full-text

DOCUMENT NUMBER: 143:229842

TITLE: Preparation of thieno[2,3-c]pyrazole derivatives as

protein kinase inhibitors

INVENTOR(S): Fancelli, Daniele; Bindi, Simona; Varasi, Mario;

Vianello, Paola; Vioglio, Sergio; Tesei, Dania

PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy

SOURCE: PCT Int. Appl., 67 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

----WO 2005074922 A1 20050818 WO 2005-EP1021 20050202
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

```
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
              RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,
              MR, NE, SN, TD, TG
     AU 2005210114
                                                AU 2005-210114
                            Α1
                                   20050818
                                                                          20050202
                                                CA 2005-2555262
     CA 2555262
                            Α1
                                   20050818
                                                                          20050202
     EP 1711177
                            Α1
                                   20061018
                                               EP 2005-701307
                                                                          20050202
     EP 1711177
                           В1
                                   20080528
             AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1946395
                           Α
                                  20070411
                                               CN 2005-80005922
                                                                          20050202
     BR 2005007375
                                  20070710
                                               BR 2005-7375
                            Α
                                                                          20050202
                           T 20070726 JP 2006-551790
T 20080615 AT 2005-701307
T3 20081116 ES 2005-701307
     JP 2007520513
                            Τ
                                  20070726
                                               JP 2006-551790
                                                                          20050202
     AT 396724
                                                                          20050202
     ES 2307144
                                                                         20050202
     US 20050187209 A1 20050825 US 2005-50360
IN 2006DN04402 A 20070810 IN 2006-DN4402
MX 2006PA08787 A 20070119 MX 2006-PA8787
NO 2006003768 A 20061102 NO 2006-3768
                                                                         20050203
                                                                         20060731
                                                                         20060802
                                                                          20060823
     KR 2006124734
                                                KR 2006-717754
                           A
                                   20061205
                                                                          20060901
                                                US 2004-541452P P 20040203
WO 2005-EP1021 W 20050202
PRIORITY APPLN. INFO.:
                     CASREACT 143:229842; MARPAT 143:229842
OTHER SOURCE(S):
GΙ
```

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted aryl or heteroaryl; R1 and R2 independently = H, alkyl, CONH2, etc. or together may form cycloalkyl ring with provisions; R3 = H, halo, OH, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as protein kinase inhibitors. Thus, e.g., II was prepared by amination of 1-(ethoxycarbonyl)-3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[2,3-c]pyrazole-5-carboxylic acid hydrochloride (preparation given) with cumylamine and subsequent deprotection. The inhibitory activity of I towards Aurora-2 kinase was evaluated utilizing a scintillation assay and it was revealed that selected compds. of the invention displayed IC50 values below 20 nM. I as protein kinase inhibitor should prove useful in the treatment of cancer. Pharmaceutical compns. comprising I are disclosed.

```
IT 648412-09-3P 836633-13-7P 862555-81-5P 862555-87-1P 862555-94-0P 862555-99-5P 862556-05-6P 862556-11-4P 862556-16-9P 862556-21-6P 862556-27-2P 862556-33-0P 862556-3P 862556-3P 862556-47-6P 862556-52-3P 862556-57-8P 862556-67-0P 862556-71-6P 862556-75-0P 862556-87-4P 862556-81-8P 862556-84-1P 862556-87-4P 862556-90-9P 862556-93-2P 862557-05-9P 862557-08-2P 862557-02-6P 862557-03-9P 862557-17-3P 862557-23-1P
```

```
862557-28-6P 862557-30-0P 862557-32-2P
862557-34-4P 862557-37-7P 862557-39-9P
862557-41-3P 862557-43-5P 862557-45-7P
862557-47-9P 862557-49-1P 862557-51-5P
862557-53-7P 862557-54-8P 862557-55-9P
862557-58-2P 862557-61-7P 862557-64-0P
862557-67-3P 862557-69-5P 862557-71-9P
862557-73-1P 862557-75-3P 862557-77-5P
862557-79-7P 862557-81-1P 862557-83-3P
862557-85-5P 862557-86-6P 862557-88-8P
862557-90-2P 862557-92-4P 862557-94-6P
862557-95-7P 862557-96-8P 862557-98-0P
862558-00-7P 862558-01-8P 862558-03-0P
862558-05-2P 862558-07-4P 862558-09-6P
862558-11-0P 862558-13-2P 862558-15-4P
862558-17-6P 862558-19-8P 862558-21-2P
862558-23-4P 862558-27-8P 862558-30-3P
862558-32-5P 862558-34-7P 862558-36-9P
862558-38-1P 862558-40-5P 862558-42-7P
862558-44-9P 862558-46-1P 862558-48-3P
862558-50-7P 862558-52-9P 862558-54-1P
862558-56-3P 862558-58-5P 862558-60-9P
862558-63-2P 862558-65-4P 862558-67-6P
862558-69-8P 862558-71-2P 862558-73-4P
862558-75-6P 862558-77-8P 862558-79-0P
862558-81-4P 862558-83-6P 862558-85-8P
862558-87-0P 862558-89-2P 862558-91-6P
862558-93-8P 862558-95-0P 862558-97-2P
862558-99-4P 862559-00-0P 862559-01-1P
862559-02-2P 862559-03-3P 862559-04-4P
862559-05-5P 862559-06-6P 862559-07-7P
862559-08-8P 862559-09-9P 862559-10-2P
862559-11-3P 862559-12-4P 862559-13-5P
862559-15-7P 862559-17-9P 862559-19-1P
862559-20-4P 862559-21-5P 862559-23-7P
862559-24-8P 862559-26-0P 862559-28-2P
862559-29-3P 862559-30-6P 862559-32-8P
862559-34-0P 862559-36-2P 862559-38-4P
862559-40-8P 862559-42-0P 862559-44-2P
862559-46-4P 862559-48-6P 862559-50-0P
862559-52-2P 862559-53-3P 862559-54-4P
862559-55-5P 862559-57-7P 862559-59-9P
862559-60-2P 862559-61-3P 862564-01-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
   (preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)
648412-09-3 CAPLUS
1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA)
INDEX NAME)
```

Absolute stereochemistry.

RN

CN

RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

RN 862555-81-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862555-87-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862555-94-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA)

INDEX NAME)

Absolute stereochemistry.

$$\mathbb{F}^{\mathbb{N}}$$

RN 862555-99-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862556-05-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862556-16-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862556-21-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862556-27-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862556-33-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA

Absolute stereochemistry.

INDEX NAME)

RN 862556-38-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-[(1R)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

$$\mathbb{F}^{\mathbb{N}}$$

RN 862556-43-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-fluorobenzoyl)amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA
INDEX NAME)

Absolute stereochemistry.

RN 862556-47-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[(4-fluorobenzoyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph} & \text{O} \\ & \text{Et} & \text{C} & \text{NH} & \text{C} \\ & \text{Et} & & \text{NH} & \text{C} \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & \\ & & \\ & \\ & \\ & & \\ & \\ & & \\ & \\ & & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\ & \\$$

RN 862556-52-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

RN 862556-57-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[(2-thienylcarbonyl)amino]-(CA INDEX NAME)

Absolute stereochemistry.

RN 862556-67-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-(4-fluorophenyl)ethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

$$\mathbb{F}^{\mathbb{N}}$$

RN 862556-71-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-phenylcyclopropyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

RN 862556-75-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]-(CA INDEX NAME)

Absolute stereochemistry.

RN 862556-78-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1R)-1-phenylpropyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862556-81-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-(CA INDEX NAME)

RN 862556-84-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862556-87-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862556-90-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862556-96-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]-N-(1-phenylcyclopropyl)-(CA INDEX NAME)

$$\underbrace{ \bigcap_{\text{Ph}} \text{NH} - \underbrace{ \bigcap_{\text{NH}} \text{S} }_{\text{NH}} \underbrace{ \bigcap_{\text{NH}} \text{NH} }_{\text{NH}} \underbrace{ \bigcap_{\text{NH}} \text{S} }_{\text{NH}} \underbrace{ \bigcap_$$

RN 862556-99-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

RN 862557-02-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 862557-05-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \text{C} \\ \text{NH} \end{array} \\ \begin{array}{c} \text{O} \\ \text{S} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{O} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{NH} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \text{N} \\ \end{array} \\ \begin{array}{c} \text{N} \\ \end{array}$$

RN 862557-08-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862557-11-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862557-14-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME) Absolute stereochemistry.

RN 862557-17-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862557-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)

$$\underbrace{ \begin{array}{c} Ph \\ NH \\ \end{array} } \underbrace{ \begin{array}{c} O \\ S \\ \end{array} } \underbrace{ \begin{array}{c} H \\ N \\ \end{array} } \underbrace{ \begin{array}{c} N \\ NH \\ \end{array} } \underbrace{ \begin{array}{c}$$

RN 862557-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

RN 862557-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]-(CA INDEX NAME)

RN 862557-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-37-7 CAPLUS

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \text{C} \\ \text{NH} \\ \end{array} \begin{array}{c} \text{O} \\ \text{S} \\ \text{NH} \\ \end{array} \begin{array}{c} \text{NH} \\ \text{NH} \\ \text{O} \\ \end{array} \begin{array}{c} \text{CH}_2 \\ \text{NH}_2 \\ \text{O} \\ \end{array}$$

RN 862557-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-41-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

RN 862557-43-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-45-7 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[[4-[[[5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-1H-thieno[2,3-c]pyrazol-3-yl]amino]carbonyl]phenyl]methyl]-, 1,1-dimethylethyl ester (CA INDEX

RN 862557-47-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(4-fluoro-1-piperidinyl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-49-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1-piperazinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-51-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1H-imidazol-1-ylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-53-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(3-thiazolidinylmethyl)benzoyl]amino]-

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \end{array} \begin{array}{c} \text{C} \\ \text{NH} \\ \end{array} \begin{array}{c} \text{C} \\ \text{S} \\ \end{array} \begin{array}{c} \text{H} \\ \text{N} \\ \text{NH} \\ \end{array} \begin{array}{c} \text{C} \\ \text{H2} \\ \end{array} \begin{array}{c} \text{CH2} \\ \text{N} \\ \end{array} \begin{array}{c} \text{S} \\ \text{S} \\ \end{array}$$

RN 862557-54-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-55-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-58-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Me} & \text{O} & \text{S} & \text{H} \\ \hline & \text{C} & \text{NH} & \text{C} & \text{S} & \text{H} \\ & \text{NH} & \text{C} & \text{NH} & \text{C} \\ \end{array}$$

RN 862557-61-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA
INDEX NAME)

RN 862557-64-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862557-67-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(3-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862557-69-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(4-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862557-71-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[4-(1,1-dimethylethyl)-1-piperazinyl]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-73-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c} \text{F} \\ \text{Ne} \\ \text{Me} \\ \end{array}$$

RN 862557-75-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-77-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(2-phenylacetyl)amino]- (CA INDEX NAME)

RN 862557-79-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(dimethylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)(CA INDEX NAME)

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \text{C} \\ \text{NH} \\ \text{C} \\ \text{S} \\ \text{NH} \\ \text{S} \\ \text{NH} \\ \text{NH} \\ \text{C} \\ \text{CH}_2 \\ \text{NMe}_2 \\ \text{CH}_2 \\ \text{CH}_2 \\ \text{NMe}_2 \\ \text{CH}_2 \\ \text{CH}_2$$

RN 862557-81-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-(CA INDEX NAME)

RN 862557-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[(cyclobutylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)-(CA INDEX NAME)

$$Me = C - NH - C$$

$$Me = Me$$

$$Me = NH - C$$

RN 862557-85-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[[methyl(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-86-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[(cyclopentylamino)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-88-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[[bis(1-methylethyl)amino]methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-90-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(aminomethyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862557-92-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-94-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} OMe & Me \\ \hline \\ C & NH \\ \hline \end{array}$$

RN 862557-95-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862557-96-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-pyrrolidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\stackrel{\text{MeO}}{\longrightarrow} \stackrel{\text{Me}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{S}}{\longrightarrow} \stackrel{\text{H}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{CH}$$

RN 862557-98-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\stackrel{\text{MeO}}{\longrightarrow} \stackrel{\text{Me}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{S}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N$$

RN 862558-00-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-01-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(1-piperidinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\bigcup_{Me}^{OMe} \bigcup_{Me}^{Me} \bigcup_{NH}^{O} \bigcup_{NH}^{S} \bigcup_{NH}^{H} \bigcup_{NH}^{N} \bigcup_{NH$$

RN 862558-03-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862558-05-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(3-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862558-07-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1-azetidinylmethyl)benzoyl]amino]-N-[1-(4-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

$$\stackrel{\text{MeO}}{\longrightarrow} \stackrel{\text{Me}}{\longrightarrow} \stackrel{\text{NH}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{S}}{\longrightarrow} \stackrel{\text{H}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{O}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{CH}_2}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow} \stackrel{\text{N}}{\longrightarrow}$$

RN 862558-09-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-11-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-13-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinylmethyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} OMe & Me \\ \hline \\ C & NH \\ \hline \\ Me \\ \end{array}$$

RN 862558-15-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{Me} & \text{O} & \text{S} & \text{H} \\ \hline \\ \text{C} & \text{NH} & \text{C} & \text{S} & \text{H} \\ \hline \\ \text{Me} & \text{NH} & \text{C} & \text{CH}_2 & \text{N} \\ \end{array}$$

RN 862558-17-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-B

__Me

___Me

RN 862558-19-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-B

RN 862558-21-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & &$$

RN 862558-23-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

PAGE 1-B

___Me

RN 862558-27-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862558-30-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862558-32-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862558-34-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862558-36-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

$$\underset{M \in \mathcal{O}}{\text{Me}} = \underset{M \in \mathcal{O}}{\text{NH}} = \underset{M \in \mathcal$$

RN 862558-38-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[(1-methyl-4-piperidinyl)oxy]benzoyl]amino]- (CA INDEX NAME)

RN 862558-40-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-

RN 862558-42-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[(cyclopropylamino)methyl]benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} OMe & Me & O \\ \hline C & NH & C \\ \hline Me & NH & C \\ \hline \end{array}$$

RN 862558-44-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)

RN 862558-46-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-[[(1-methylethyl)amino]methyl]benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} \text{OMe} & \text{Me} & \text{O} \\ \hline & \text{C} & \text{NH} & \text{C} \\ \hline & \text{N} & \text{N} & \text{O} \\ \hline & \text{N} & \text{NH} & \text{C} \\ \hline \end{array}$$

RN 862558-48-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-50-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-[(hexahydro-1H-azepin-1-yl)methyl]benzoyl]amino]- (CA INDEX NAME)

RN 862558-52-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(1H-pyrazol-1-ylmethyl)benzoyl]amino]-(CA INDEX NAME)

RN 862558-54-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-56-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-58-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-methoxybenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-60-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[3-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-63-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(dimethylamino)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-65-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-furanylcarbonyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-67-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-(1-methyl-1-phenylethyl)-3-[(3-thienylcarbonyl)amino]- (CA INDEX NAME)

RN 862558-69-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrrol-3-yl)carbonyl]amino]-(CA INDEX NAME)

RN 862558-71-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]-(CA INDEX NAME)

RN 862558-73-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-

(CA INDEX NAME)

RN 862558-75-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-pyridinylcarbonyl)amino]- (CA INDEX NAME)

RN 862558-77-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(3-pyridinylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c} \text{Ph} \\ \text{Me} \\ \text{C} \\ \text{NH} \\ \text{C} \\ \text{S} \\ \text{S} \\ \text{N} \\ \text{N} \\ \text{NH} \\ \text{NH} \\ \text{O} \\ \text{NH} \\ \text{O} \\ \text{O} \\ \text{NH} \\ \text{O} \\ \text{O} \\ \text{NH} \\ \text{O} \\ \text$$

RN 862558-79-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[(4-pyridinylcarbonyl)amino]- (CA INDEX NAME)

RN 862558-81-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-chlorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862558-83-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-(1-methyl-1-phenylethyl)-3-[(4-phenoxybenzoyl)amino]- (CA INDEX NAME)

RN 862558-85-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-87-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

$$\begin{array}{c} \text{MeO} \\ \\ \\ \text{Me} \end{array} \begin{array}{c} \text{NH} \\ \\ \\ \text{NH} \end{array} \begin{array}{c} \text{NH} \\ \\ \\ \\ \text{NH} \end{array} \begin{array}{c} \text{NH} \\ \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \text{NH} \\ \\ \\ \\ \\ \\ \\ \end{array} \begin{array}{c} \text{NH} \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array}$$

RN 862558-89-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

piperazinyl)benzoyl]amino]- (CA INDEX NAME)

$$\underbrace{ \begin{array}{c} \text{OMe} \\ \text{Me} \\ \text{Me} \\ \end{array} }_{\text{Me}} \underbrace{ \begin{array}{c} \text{N} \\ \text{$$

RN 862558-91-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

$$\underset{M \in \mathcal{O}}{\text{Me}} \bigcup_{N \in \mathcal{O}} \bigcup_{N \in \mathcal{O$$

RN 862558-93-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862558-95-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & \text{Ph} & \text{O} \\ & \text{Et} & \text{C} & \text{NH} & \text{C} \\ & \text{Et} & & & & \\ & & & & & \\ \end{array}$$

RN 862558-97-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-phenylcyclopentyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

RN 862558-99-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA
INDEX NAME)

RN 862559-00-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA
INDEX NAME)

$$\begin{array}{c} \text{Me} \\ \text{Me} \\ \text{Me} \\ \end{array}$$

RN 862559-01-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-2-(4-morpholinyl)-1-phenylethyl]-3-[[4(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862559-02-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 862559-03-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862559-04-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(4-fluorobenzoyl)amino]-N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862559-05-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-ethyl-1-phenylpropyl)-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-06-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]-3-[(2-thienylcarbonyl)amino]-(CA INDEX NAME)

Absolute stereochemistry.

RN 862559-07-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-(1-phenylcyclopentyl)- (CA INDEX NAME)

RN 862559-08-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\$$

RN 862559-09-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-chlorophenyl)-1-methylethyl]-3-[(4-fluorobenzoyl)amino]- (CA INDEX NAME)

RN 862559-10-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
3-[(4-methoxybenzoyl)amino]-N-(1-phenylcyclopropyl)- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ &$$

RN 862559-11-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-phenylcyclopropyl)-3-[[4-(trifluoromethoxy)benzoyl]amino]- (CA INDEX NAME)

RN 862559-12-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-(1-methyl-1-phenylethyl)-3-[[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]amino]- (CA INDEX NAME)

RN 862559-13-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,
N-[(1S)-1-methyl-2-(4-morpholinyl)-1-phenylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862559-15-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-(4-pyridinyl)ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-17-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-19-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-20-4 CAPLUS

$$\begin{array}{c|c} & & & & \\ &$$

RN 862559-21-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-23-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[[4-(methylsulfonyl)benzoyl]amino]- (CA INDEX NAME)

RN 862559-24-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(1,1-dioxido-4-thiomorpholinyl)benzoyl]amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862559-26-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\$$

RN 862559-28-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]- (CA INDEX NAME)

RN 862559-29-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-methyl-1-[3-(methylsulfonyl)phenyl]ethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]- (CA INDEX NAME)

$$Me = \bigcup_{M=0}^{\infty} \bigcup_{M=0}^{M=0} \bigcup_{M=0}^{\infty} \bigcup_{M=0}^{$$

RN 862559-30-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & &$$

RN 862559-32-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-34-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-(CA INDEX NAME)

RN 862559-36-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

RN 862559-38-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

$$\bigcup_{Me}^{OMe} \bigcup_{Me}^{Me} \bigcup_{NH}^{O} \bigcup_{Me}^{S} \bigcup_{NH}^{H} \bigcup_{NH}^{N} \bigcup_{NH}^{O} \bigcup_{NH}^{S} \bigcup_{NH}$$

RN 862559-40-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} \text{MeO} & \begin{array}{c} \text{Me} \\ \\ \end{array} \\ \begin{array}{c} \text{NH} \\ \end{array} \\ \begin{array}{c$$

RN 862559-42-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-methoxyphenyl)-1-methylethyl]-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\$$

RN 862559-44-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ &$$

RN 862559-46-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(3-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)

RN 862559-48-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)

$$\begin{array}{c|c} F & Me \\ \hline \\ Me & NH \\ \hline \end{array} \begin{array}{c} O \\ \hline \\ Me & NH \\ \hline \end{array} \begin{array}{c} O \\ \hline \\ NH \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} O \\ \hline \\ NH \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c} O \\ \hline \\ NH \\ \hline \end{array} \begin{array}{c} O \\ \hline \end{array} \begin{array}{c$$

RN 862559-50-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-furanylcarbonyl)amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\$$

RN 862559-52-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-fluorophenyl)-1-methylethyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ &$$

RN 862559-53-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(2-methoxyphenyl)-1-methylethyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]- (CA INDEX NAME)

RN 862559-54-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]- (CA INDEX NAME)

RN 862559-55-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862559-57-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-morpholinyl)benzoyl]amino]-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

RN 862559-59-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-(benzoylamino)-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862559-60-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(3-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862559-61-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[(2-fluorobenzoyl)amino]-N-(1-methyl-1-phenylethyl)- (CA INDEX NAME)

RN 862564-01-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-[1-(4-fluorophenyl)-1-methylethyl]-3-[[4-[(4-methyl-1-piperazinyl)methyl]benzoyl]amino]- (CA INDEX NAME)

```
ΙT
     1044679-83-5P 1044679-84-6P 1044679-86-8P
     1044679-88-0P 1044679-91-5P 1044679-93-7P
     1044679-94-8P 1044679-96-0P 1044679-99-3P
     1044680-01-4P 1044680-02-5P 1044680-04-7P
     1044680-07-0P 1044680-09-2P 1044680-10-5P
     1044680-12-7P 1044680-15-0P 1044680-17-2P
     1044680-20-7P 1044680-24-1P 1044680-25-2P
     1044680-27-4P 1044680-28-5P 1044680-32-1P
     1044680-34-3P 1044680-35-4P 1044680-40-1P
     1044680-42-3P 1044680-45-6P 1044680-47-8P
     1044680-48-9P 1044680-50-3P 1044680-53-6P
     1044680-55-8P 1044680-57-0P 1044680-58-1P
     1044680-61-6P 1044680-64-9P 1044680-65-0P
     RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP
     (Preparation); RACT (Reactant or reagent)
        (preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)
RN
     1044679-83-5 CAPLUS
CN
     INDEX NAME NOT YET ASSIGNED
```

Absolute stereochemistry.

RN 1044679-84-6 CAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 1044679-86-8 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1R)-1-(4fluorophenyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044679-88-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1R)-1-(4-fluorophenyl)ethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044679-91-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-furanylcarbonyl)amino]-5-[[(1-phenylcyclopropyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1044679-93-7 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044679-94-8 CAPLUS CN INDEX NAME NOT YET ASSIGNED

RN 1044679-96-0 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044679-99-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-furanylcarbonyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 1044680-01-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid,

3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 1044680-02-5 CAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 1044680-04-7 CAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

RN 1044680-07-0 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044680-09-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-2-(4-morpholinyl)-1phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044680-10-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1R)-1-phenylpropyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-,
ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044680-12-7 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-5-[[(1-phenylcyclopropyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1044680-15-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(4-fluorobenzoyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 1044680-17-2 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-20-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-furanylcarbonyl)amino]-, 1-ethyl ester (CA INDEX NAME)

RN 1044680-24-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-25-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(4-fluorobenzoyl)amino]-5-[[(1-phenylcyclopropyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)

RN 1044680-27-4 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[(4-fluorobenzoyl)amino]-,
ethyl ester (CA INDEX NAME)

RN 1044680-28-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[[(1S)-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044680-32-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1044680-34-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 1044680-35-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-thienylcarbonyl)amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 1044680-40-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(4-fluorobenzoyl)amino]-, 1-ethyl ester (CA INDEX NAME)

RN 1044680-42-3 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-45-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-47-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1044680-48-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-5-[[(1-phenylcyclopentyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1044680-50-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1044680-53-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-5-[[[(1R)-1-phenylpropyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1044680-55-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-phenylcyclopropyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1044680-57-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-furanylcarbonyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1044680-58-1 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-61-6 CAPLUS

CN INDEX NAME NOT YET ASSIGNED

RN 1044680-64-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[(1-methyl-1H-pyrrol-2-yl)carbonyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 1044680-65-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[(2-thienylcarbonyl)amino]-, 1-ethyl ester (CA INDEX NAME)

IT 1044680-19-4P 1044680-39-8P

RL: PRPH (Prophetic); SPN (Synthetic preparation); PREP (Preparation) (preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)

RN 1044680-19-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1-ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

RN 1044680-39-8 CAPLUS CN INDEX NAME NOT YET ASSIGNED

```
1056901-68-8 1056901-69-9 1056901-72-4
ΙT
     1056901-92-8 1056901-93-9 1056902-05-6
     1056902-08-9 1056902-09-0 1056902-10-3
     1056902-13-6 1056902-17-0 1056902-18-1
     1056902-24-9 1056902-36-3 1056902-37-4
     1056902-38-5 1056902-39-6 1056902-40-9
     1056902-41-0 1056902-42-1 1056902-44-3
     1056902-45-4 1056902-46-5 1056902-47-6
     1056902-48-7 1056902-51-2 1056902-52-3
     1056902-53-4 1056902-54-5 1056902-62-5
     1056902-75-0 1056902-85-2 1056902-87-4
     1056902-88-5 1056902-93-2 1056903-06-0
     1056903-07-1 1056903-08-2 1056903-09-3
     1056903-10-6 1056903-11-7 1056903-12-8
     1056903-13-9 1056903-14-0 1056903-16-2
     1056903-18-4 1056903-19-5 1056903-20-8
     1056903-21-9 1056903-22-0 1056903-23-1
     1056903-24-2 1056903-25-3 1056903-26-4
     1056903-27-5 1056903-28-6 1056903-29-7
     1056903-30-0 1056903-31-1 1056903-32-2
     1056903-33-3 1056903-34-4 1056903-35-5
     1056903-36-6 1056903-37-7 1056903-38-8
     1056903-39-9 1056903-40-2 1056903-41-3
     1056903-44-6 1056903-45-7 1056903-46-8
     1056903-91-3
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (preparation of thieno[2,3-c]pyrazole derivs. as protein kinase inhibitors)
RN
     1056901-68-8 CAPLUS
CN
     1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
     3-amino-5-[[(1-phenylcyclopropyl)amino]carbonyl]-, ethyl ester (CA INDEX
     NAME)
```

RN 1056901-69-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(3-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 1056901-72-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(2-fluorophenyl)-1-methylethyl]- (CA INDEX NAME)

RN 1056901-92-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(4-fluorophenyl)-1-methylethyl]-(CA INDEX NAME)

RN 1056901-93-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(2-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

RN 1056902-05-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(3-methoxyphenyl)-1-methylethyl]- (CA INDEX NAME)

RN 1056902-08-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(chloromethyl)benzoyl]amino]-N-[1-(4-methoxyphenyl)-1-methylethyl]-(CA INDEX NAME)

RN 1056902-09-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-methoxybenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-10-3 CAPLUS

CN

1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[(3-methoxybenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-,
ethyl ester (CA INDEX NAME)

RN 1056902-13-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-methoxybenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-17-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[3-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-18-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(dimethylamino)benzoyl]amino]-5-[[(1-methyl-1phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-24-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(3-furanylcarbonyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-36-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(3-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-37-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[(1-methyl-1H-pyrrol-3-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-38-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[(1-methyl-1H-pyrazol-3-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-39-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-40-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(2-pyridinylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-41-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(3-pyridinylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-42-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(4-pyridinylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-44-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-chlorobenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-45-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[(4-phenoxybenzoyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-46-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-47-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-48-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-51-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-52-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-53-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-phenylcyclopentyl)amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-54-5 CAPLUS

CN

1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-62-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056902-75-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[(1S)-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-3-[[4-(trifluoromethoxy)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056902-85-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-87-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[4-[2-(dimethylamino)ethoxy]benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056902-88-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(4-fluorobenzoyl)amino]-5-[[[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056902-93-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-ethyl-1-phenylpropyl)amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-06-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1S)-1-phenyl-2-(1-piperidinyl)ethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056903-07-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[(1-

phenylcyclopentyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-08-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-chlorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-chlorophenyl)-1-methylethyl]amino]carbonyl]-3-[(4-fluorobenzoyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-10-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,

3-[(4-methoxybenzoyl)amino]-5-[[(1-phenylcyclopropyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-11-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[(1-phenylcyclopropyl)amino]carbonyl]-3-[[4(trifluoromethoxy)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-12-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[[6-(4-morpholinyl)-3-pyridinyl]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-13-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[(1S)-1-methyl-2-(4-morpholinyl)-1-phenylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056903-14-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-methyl-1-(4-pyridinyl)ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-16-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-18-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-19-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-20-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-21-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4(methylsulfonyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-22-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[4-(1,1-dioxido-4-thiomorpholinyl)benzoyl]amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-23-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-24-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-5-[[[1-methyl-1-[3-(1-pyrrolidinyl)phenyl]ethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-25-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-methyl-1-[3-(methylsulfonyl)phenyl]ethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-26-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-27-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-28-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-29-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-30-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-31-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-32-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[(2-thienylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-33-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-34-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-35-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[(2-furanylcarbonyl)amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-36-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-furanylcarbonyl)amino]-5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-37-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-38-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(2-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-39-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(4-fluorophenyl)-1-methylethyl]amino]carbonyl]-3-[[(1-methyl-1H-pyrazol-5-yl)carbonyl]amino]-, ethyl ester (CA INDEX NAME)

RN 1056903-40-2 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[[(1R)-1phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056903-41-3 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-[[4-(4-morpholinyl)benzoyl]amino]-5-[[[(1S)-1phenylethyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.

RN 1056903-44-6 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
3-(benzoylamino)-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester
(CA INDEX NAME)

RN 1056903-45-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(3-fluorobenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-46-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[(2-fluorobenzoyl)amino]-5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)

RN 1056903-91-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 5-[[[1-(3-methoxyphenyl)-1-methylethyl]amino]carbonyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

 RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 862559-62-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-amino-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 862559-63-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-morpholinyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 862559-65-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(4-morpholinyl)benzoyl]amino]-, 1-ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

RN 862559-67-9 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid,
5-[[(1-methyl-1-phenylethyl)amino]carbonyl]-3-[[4-(4morpholinyl)benzoyl]amino]-, ethyl ester (CA INDEX NAME)

RN 862559-69-1 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
1-[4-(4-methyl-1-piperazinyl)benzoyl]-3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)

RN 862559-71-5 CAPLUS
CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,
3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, 1,1-dimethylethyl ester
(CA INDEX NAME)

RN 862559-73-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

RN 862559-75-9 CAPLUS


CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(chloromethyl)benzoyl]amino]-, 5-(1,1-dimethylethyl) 1-ethyl ester (CA INDEX NAME)

RN 862559-77-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1,5-dicarboxylic acid, 3-[[4-(chloromethyl)benzoyl]amino]-, 1-ethyl ester (CA INDEX NAME)

RN 862559-80-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxylic acid, 3-[[4-(chloromethyl)benzoyl]amino]-5-[[(1-methyl-1phenylethyl)amino]carbonyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 11 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN 2005:99176 CAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 142:198080

Preparation of substituted thieno[2,3-c]pyrazoles and TITLE:

their use as medicinal products for cancer and

neurodegenerative diseases

Bigot, Antony; Clerc, Francois; Doerflinger, Gilles; INVENTOR(S):

Mignani, Serge; Minoux, Herve

Aventis Pharma S.A., Fr. PATENT ASSIGNEE(S):

SOURCE: U.S. Pat. Appl. Publ., 15 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
				_		
US 20050026984	A1	20050203	US 2004-900549		20040728	
PRIORITY APPLN. INFO.:			FR 2003-9284	Α	20030729	
			US 2003-500614P	P	20030905	

OTHER SOURCE(S): CASREACT 142:198080; MARPAT 142:198080

GΙ

$$R^2$$
 S
 M
 N
 N

The present invention relates in particular to novel chemical compds., AΒ particularly novel substituted thieno[2,3-c]pyrazoles I [R1 = XY; X = ; Y = (un) substituted; R2 = XY, ; R = H, alkyl; n = 0 - 2; a = 1, 2; all above are optionally substituted with alkyl, aryl, amino or alkoxy; with the proviso

that when R2 = R1, then X \neq NHCO, NHSO2], to the compns. containing them and to their use as medicinal products for treating cancers and also neurodegenerative diseases. Thus, 3-phenyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid N-benzyl-N-methylamide [I; R1 = Ph, R2 = CONMeCH2Ph] was prepared from 1-benzyl-5-chloro-3-phenylpyrazole-4-carboxaldehyde via cyclocondensation with HSCH2CO2Et, chlorination with SOC12 and amidation with PhCH2NHMe. The protein kinase inhibitory activity of I was tested against FAK, KDR, Aurora 2, Src and Tie2 (Ki = 100 - 5000 nM).

IT 836633-20-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and N-deprotection of; preparation of thieno[2,3-c]pyrazole derivs.

for use in treatment of cancer and neurodegenerative diseases)

RN 836633-20-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide,

1-(1-ethoxyethyl)-N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]-(CA INDEX NAME)

IT 836633-22-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and amidation of, with cumylamine; preparation of thieno[2,3-c]pyrazole derivs. for use in treatment of cancer and neurodegenerative diseases)

RN 836633-22-8 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

1-(1-ethoxyethy1)-3-[(2-thieny1carbony1)amino]-, ethy1 ester (CA INDEX NAME)

IT 836633-13-7P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of thieno[2,3-c]pyrazole derivs. for use in treatment of cancer

and neurodegenerative diseases)

RN 836633-13-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, N-(1-methyl-1-phenylethyl)-3-[(2-thienylcarbonyl)amino]- (CA INDEX NAME)

L3 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1001062 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 142:113983

TITLE: Mononuclear heterocyclic rearrangement: Synthesis of

[5:5] bicyclic [c]-fused 3-aminopyrazoles via the N-N

bond formation strategy

AUTHOR(S): Berry, David A.; Chien, Tun-Cheng; Townsend, Leroy B.

CORPORATE SOURCE: Department of Medicinal Chemistry, College of

Pharmacy, The University of Michigan, Ann Arbor, MI,

48109-1065, USA

SOURCE: Heterocycles (2004), 63(11), 2475-2494

CODEN: HTCYAM; ISSN: 0385-5414

PUBLISHER: Japan Institute of Heterocyclic Chemistry

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:113983

The formation of [5:5] bicyclic heterocyclic ring systems containing [c]pyrazoles, i.e. imidazo[4,5-c]pyrazole, pyrazolo[3,4-c]pyrazole, pyrrolo[2,3-c]pyrazole, and pyrazolo[3,4-d][1,2,3]triazole, was accomplished by mononuclear heterocyclic rearrangement (MHR). The core pyrazole ring was formed based on a N-N bond formation strategy. The ring transformation of 5-substituted 3-(2-aminoary1)-1,2,4-oxadiazoles, under thermal conditions to the corresponding [5:5] bicyclic [c]-fused 3-aminopyrazole ring systems was promoted by sodium hydride in DMF or DMSO. The ring transformation by MHR has provided a practical and general synthetic method for the derivs. of 3-aminoimidazo[4,5-c]pyrazole, 3-aminopyrrolo[2,3-c]pyrazole, and 6-aminopyrazolo[3,4-d][1,2,3]triazole.

IT 821004-47-1P

RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of N-[cyano(pyrrolo[2,3-c]pyrazolyl]benzamide using [amino(iminomethyl)pyrrolecarboxamide as synthetic intermediate)

RN 821004-47-1 CAPLUS

CN Benzamide, N-[5-cyano-1,6-dihydro-6-(phenylmethyl)pyrrolo[2,3-c]pyrazol-3-yl]-4-nitro- (CA INDEX NAME)

$$\begin{array}{c|c} \text{Ph-CH}_2 & \text{H} & \text{O} \\ \text{NC} & \text{N} & \text{N} & \text{O} \\ \hline & & & \text{N} & \text{N} \\ \end{array}$$

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2004:414631 CAPLUS Full-text

DOCUMENT NUMBER: 140:423660

TITLE: Preparation of thieno[3,2-c]pyridines and related

compounds as antiinflammatory agents

INVENTOR(S): Burkitt, Simon A.; Cardozo, Mario G.; Cushing, Timothy

D.; DeGraffenreid, Michael R.; Farthing, Christopher N.; Hao, Xiaolin; Jaen, Juan C.; Jiao, Xian Yun; Kopecky, David J.; Labelle, Marc; Lively, Sarah E.;

McMinn, Dustin L.; Rasmussen, Sven P.; Shin, Youngsook; Smith, Andrew; Smith, Marie-Louise

PATENT ASSIGNEE(S): Tularik Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 70 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA.	PATENT NO. KIND			D	DATE APPLICATION NO.						DATE								
US	2004	0097	485		A1		20040520 US 2003					003-666857					20030919		
US	7199	119			В2		20070403												
CA	2502	429			A1		20040521 CA 2003-2502429						20030919						
WO	2004	0412	85		A1		2004	0521		WO 2	003-	US29	143		2	0030	919		
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AΖ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,		
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FI,	GB,	GD,	GE,	GH,		
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KΕ,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,		
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	ΝI,	NO,	NΖ,	OM,		
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,	ТJ,	TM,	TN,		
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW					
	RW:	GH,	GM,	KΕ,	LS,	MW,	${ m MZ}$,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,		
		KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,		
		FI,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC,	NL,	PT,	RO,	SE,	SI,	SK,	TR,		
		BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	$\mathrm{ML}_{m{\prime}}$	MR,	ΝE,	SN,	TD,	ΤG		
AU	2003	2707	01		A1		20040607 AU 2003-270701							20030919					
EP	1556	053			A1		2005	0727		EP 2	003-	7524	10		2	0030	919		
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	ΙΤ,	LI,	LU,	NL,	SE,	MC,	PT,		
		IE,	SI,	LT,	LV,	FI,	RO,	MK,	CY,	AL,	TR,	BG,	CZ,	EE,	HU,	SK			
JP	2006	5123	13		Τ		2006	0413		JP 2	004-	5499	54		2	0030	919		
US	2007	0155	777		A1		2007	0705		US 2	007-	7098	95		2	0070	221		
PRIORIT:	Y APP	LN.	INFO	.:						US 2	002-	4225	31P		P 2	0021	031		
										US 2	003-	6668	57		A3 2	0030	919		
										WO 2	003-	US29	143	,	W 2	0030	919		

OTHER SOURCE(S): MARPAT 140:423660

GΙ

The invention relates to title fused heterobicyclic compds. QLWR1R2 (I) AB [wherein W = 5-6, 6-6, or 5-5 fused bicyclic ring system wherein one or both rings are aromatic, containing N and 0-3 addnl. N, O, or S; R1 = carbamoyl, acyl, hydroxyiminomethyl, acylamino, sulfamoyl, heteroaryl, etc.; R2 = (un) substituted amino, heterocyclyl, OH; L = bond, alkylene, CO, CONR3, SO2NR3, CR3=CR4, O, S, NR3; R3 and R4 = independently H, (cyclo)alkyl, (hetero)aryl(alkyl), heterocyclyl; Q = cycloalkyl, (cyclo)alkenyl, alkynyl, alkoxy, halo, (hetero)aryl, heterocyclyl; with provisos; and pharmaceutically acceptable salts, hydrates, solvates, or prodrugs thereof], which were prepared as inhibitors of IKKlpha and IKKeta enzymes, mediators of TNF-lpha and IL-1 induced IKB phosphorylation and degradation For example, reaction of 2-bromo-7-cyano-4-(p-methoxybenzylamino)thieno[3,2-c]pyridine with concentrated H2SO4 gave 2-bromo-7-carboxamido-4-aminothieno[3,2-c]pyridine●H2SO4, which was coupled with 3,4,5-trimethoxybenzeneboronic acid in the presence of K2CO3 and PdCl2(dppf):DCM complex in DMF and H2O to afford II. All exemplified compds. inhibited recombinant, full-length IKK β enzyme with IC50 values of \leq 10 μ M, and selected compds. displayed IC50 values $\leq 10~\mu M$ against recombinant, full-length IRAK-1 and IRAK-4 enzymes. Thus, I and their pharmaceutical compns. are useful in the treatment of inflammatory, immunoregulatory, metabolic, infectious, and cell proliferative diseases or conditions (no data). 690636-53-4P TТ

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(IKK inhibitor; preparation of thieno[3,2-c]pyridines and related fused heterobicyclic compds. as antiinflammatory agents)

RN 690636-53-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-1-carboxamide, 3-amino-5-phenyl- (CA INDEX NAME)

REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2004:120860 CAPLUS Full-text DOCUMENT NUMBER: 140:163864

TITLE: Preparation of condensed heterocyclic pyrazole

derivatives as protein kinase inhibitors

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele;

Pittala, Valeria; Varasi, Mario Pharmacia Italia S.P.A, Italy

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A, SOURCE: PCT Int. Appl., 68 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

P <i>P</i>					KIND DATE				APPLICATION NO.									
WC											2003-					0030	 711	
	W:	ΑE,	AG,	AL,	AM,	AT,	AU,	AZ,	ΒA,	BB	, BG,	BR,	BY,	BZ,	CA,	CH,	CN,	
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC	, EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE	, KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN	, MW,	MX,	MZ,	NI,	NO,	NZ,	OM,	
		PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE	, SG,	SK,	SL,	SY,	ΤJ,	TM,	TN,	
		TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN	, YU,	ZA,	ZM,	ZW				
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	AM,	ΑZ,	BY,	
		KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG	, СН,	CY,	CZ,	DE,	DK,	EE,	ES,	
		FΙ,	FR,	GB,	GR,	HU,	IE,	ΙΤ,	LU,	MC	, NL,	PT,	RO,	SE,	SI,	SK,	TR,	
			•							_	, GW,	•	•		•			
											2003-							
											2003-							
										EΡ	2003-	7661	52		2	0030	711	
EF	1530	573			В1		2008	0319										
	R:										, IT,						PT,	
		,	,	,	,	,	,	,	•		, TR,	,			,			
	2003										2003-							
JF	2005 3896	5372	88		Τ						2004-					0030		
AT	3896	58			Τ						2003-							
	2303										2003-					0030		
	2005										2005-					0050		
	2006				A1		2006	0608			2005-					0050		
PRIORIT	Y APP	LN.	INFO	.:							2002-							
										WO	2003-	EP75	31		W 2	0030	711	
OTHER S	OURCE	(S):			MAR:	PAT	140:	1638	64									

$$\mathbb{R}^{1} \xrightarrow{\mathbb{R}^{2}} \mathbb{N}^{\mathbb{N}}$$

GΙ

The title compds. I [wherein X = 0, S, S0, S02, or NR'; R and R1 = independently H, (un)substituted R', COR', CO2R', CONHR', CONR'R'', S02R', S02NHR', or S02NR'R''; R' and R'' = independently H, (un)substituted alkyl, heterocyclyl, aryl, or aralkyl; R2 = (un)substituted R', CH2OR', or OR'] or pharmaceutically acceptable salts thereof are prepared For example, the compound II was prepared in a five-step synthesis starting from Et 4-cyano-5-

(methylthio)thiophene-2-carboxylate. I can be used as protein kinase inhibitors, and are useful for the treatment of cancer (no data).


IT 656235-18-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of condensed heterocyclic pyrazole derivs. as protein kinase inhibitors)

RN 656235-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)



L3 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 2004:60516 CAPLUS Full-text

DOCUMENT NUMBER: 140:111412

TITLE: Preparation of heterobicyclic pyrazole derivatives as

kinase inhibitors

INVENTOR(S): Tonani, Roberto; Bindi, Simona; Fancelli, Daniele;

Pittala, Valeria; Danello, Matteo

PATENT ASSIGNEE(S): Pharmacia Italia S.P.A., Italy

SOURCE: PCT Int. Appl., 76 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE		
WO 2004007504	A1 20040122	A1 20040122 WO 2003-EP7529			
W: AE, AG, AL	A, AM, AT, AU, AZ,	BA, BB, BG, BR, BY, E	BZ, CA, CH, CN,		
CO, CR, CU	J, CZ, DE, DK, DM,	DZ, EC, EE, ES, FI, G	GB, GD, GE, GH,		
GM, HR, HU	U, ID, IL, IN, IS,	JP, KE, KG, KP, KR, K	KZ, LC, LK, LR,		
LS, LT, LU	J, LV, MA, MD, MG,	MK, MN, MW, MX, MZ, N	NI, NO, NZ, OM,		
PG, PH, PL	, PT, RO, RU, SC,	SD, SE, SG, SK, SL, S	SY, TJ, TM, TN,		
·		VC, VN, YU, ZA, ZM, Z			
RW: GH, GM, KE	I, LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZM, Z	ZW, AM, AZ, BY,		
KG, KZ, MD	RU, TJ, TM, AT,	BE, BG, CH, CY, CZ, D	DE, DK, EE, ES,		
· · ·		LU, MC, NL, PT, RO, S			
·		GN, GQ, GW, ML, MR, N			
CA 2492673		CA 2003-2492673			
AU 2003254337		AU 2003-254337			
		BR 2003-12722			
		EP 2003-763818	20030711		
EP 1534716					
· · ·		GB, GR, IT, LI, LU, N			
· · ·		CY, AL, TR, BG, CZ, E	· ·		
JP 2006501191					
AT 393159	T 20080515	AT 2003-763818	20030711		

ES 2304531	Т3	20081016	ES	2003-763818		20030711
TW 284645	В	20070801	TW	2003-92119120		20030714
MX 2005PA00629	A	20050425	MX	2005-PA629		20050114
PRIORITY APPLN. INFO.:			US	2002-396174P	P	20020717
			WO	2003-EP7529	W	20030711

OTHER SOURCE(S): MARPAT 140:111412

GΙ

The title compds. [I; X = NR', O, S, SO, SO2; R, R1 = H, R', COR', CO2R', CONHR', CONR'R'', SO2R', SO2NHR', SO2NR'R'' (wherein R', R'' = H, alkyl, aryl, etc.); R2 = R', CH2OR', OR'] which may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer, were prepared E.g., a multi-step synthesis of Me 3-[(4-morpholin-4-ylbenzoyl)amino]-1H-thieno[3,2-c]pyrazole-5-carboxylate which showed IC50 of <100 nM, <1000nM, and of <500 nM against Aurora-2, cdc7, and PAK-4, resp., was given. The pharmaceutical compns. comprising the compds. I are disclosed.

II 648412-09-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterobicyclic pyrazole derivs. as kinase inhibitors)

RN 648412-09-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3-[[4-(4-methyl-1-piperazinyl)benzoyl]amino]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1998:402031 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 129:122635

ORIGINAL REFERENCE NO.: 129:25129a,25132a

TITLE: The reaction of phenacylmalononitrile with hydrazines:

synthesis of new pyridazinones and

pyrazolo[1,5-a]pyrimidines

AUTHOR(S): Elnagdi, Mohamed Hilmy; El-Ghamry, Ibrahim; Kandeel,

Ezz; Abdel Rahman, A. H.; Al-Naggar, Abdul Aziz; Amer,

Samir; Riad, Mohamed

CORPORATE SOURCE: Department of Chemistry, Faculty of Science,

University of Kuwait, Safat, 13060, Kuwait

SOURCE: Gazzetta Chimica Italiana (1997), 127(12), 791-794

CODEN: GCITA9; ISSN: 0016-5603

PUBLISHER: Societa Chimica Italiana

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:122635

AB The reaction of phenacylmalononitrile with hydrazine hydrate affords a mixture of 3,5-diamino-4-phenacylpyrazole (I), and 6-oxo-3-phenyl-1,4,5,6-

tetraydropyridazine-5-carbonitrile. The reaction of I with a variety of reagents, that enabled the synthesis of some new pyrazolo[1,5-a]pyrimidine derivs., is described.

IT 210347-43-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of pyridazinones and pyrazolo[1,5-a]pyrimidines)

RN 210347-43-6 CAPLUS

CN 1H-Furo[2,3-c]pyrazol-3-amine, 5-phenyl- (CA INDEX NAME)

IT 210347-42-5P

RL: SPN (Synthetic preparation); PREP (Preparation) (synthesis of pyridazinones and pyrazolo[1,5-a]pyrimidines)

RN 210347-42-5 CAPLUS

CN 1H-Furo[2,3-c]pyrazole-1-propanenitrile, 3-amino-5-phenyl- (CA INDEX NAME)

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1998:239968 CAPLUS Full-text

DOCUMENT NUMBER: 129:4623

ORIGINAL REFERENCE NO.: 129:1109a,1112a

TITLE: Synthesis of thieno-heterocycles from substituted

5-(methylthio)thiophene-4-carbonitriles

AUTHOR(S): Briel, D.

CORPORATE SOURCE: Inst. Pharmazie, Fak. Biowissenschaften, Pharmazie,

Psychologie, Univ. Leipzig, Leipzig, D-04103, Germany

SOURCE: Pharmazie (1998), 53(4), 227-231

CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal LANGUAGE: German

OTHER SOURCE(S): CASREACT 129:4623

AB 5-(Methylthio)-4-thiophenenitriles were used as C3-synthons for the synthesis of thienodipyrimidines, thienopyrimidines, thienopyridines, thienopyrazoles, and pyrazolothienopyrimidines. The thienopyrazoles and

pyrazolothienopyrimidines were screened for antiulcer activity.

IT 207452-83-3P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antiulcer activity)

RN 207452-83-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid,

4-(acetylamino)-3-amino-1-methyl-, methyl ester (CA INDEX NAME)



IT 207452-82-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and antiulcer activity)

RN 207452-82-2 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 4-(acetylamino)-3-amino-, methyl ester (CA INDEX NAME)

MeO-CSNH NH2

L3 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1997:619483 CAPLUS Full-text DOCUMENT NUMBER: 127:331458

ORIGINAL REFERENCE NO.: 127:65097a,65100a

TITLE: Syntheses with heterocyclic β -enamino nitriles.

An expeditious synthetic approach to polyfunctionally substituted 5-phenyl-sulfonylthiophenes and their

fused derivatives

AUTHOR(S): Sherif, S. M.; Hussein, A. M.


CORPORATE SOURCE: Faculty Science, Cairo University, Giza, Egypt
SOURCE: Monatshefte fuer Chemie (1997), 128(6/7), 687-696

CODEN: MOCMB7; ISSN: 0026-9247

PUBLISHER: Springer
DOCUMENT TYPE: Journal
LANGUAGE: English

OTHER SOURCE(S): CASREACT 127:331458

GΙ



AB PhSO2CH2COC6H4-4-R (R = H, Br) reacts with a mixture of elemental S and CH2(CN)2 to yield the corresponding thiophenecarbonitriles I. Compound I (R = H) could be annelated to the corresponding thieno[2,3-d]pyrimidine and thieno[2,3-c]pyrazole (II) upon reaction with the N nucleophiles NH2CN and NH2OH.HCl, resp. The applicability and synthetic potency of II to develop a facile convenient route to polyfunctional thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines is reported.


IT 197861-67-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (phenylsulfonyl)thiophenes as heterocyclic enamino nitriles and their fused derivs.)

RN 197861-67-9 CAPLUS

CN 1H-Thieno[2,3-c]pyrazol-3-amine, 4-phenyl-5-(phenylsulfonyl)- (CA INDEX NAME)



L3 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1995:962283 CAPLUS Full-text

DOCUMENT NUMBER: 124:176031

ORIGINAL REFERENCE NO.: 124:32643a,32646a

TITLE: Thieno[2',3':3,4]pyrazolo[1,5-a]pyrimidines and

-triazines: synthesis of the novel ring systems

Briel, D.

CORPORATE SOURCE: Institut Pharmazie, Universitaet Leipzig, Germany

SOURCE: Pharmazie (1995), 50(10), 675-8 CODEN: PHARAT; ISSN: 0031-7144

PUBLISHER: Govi-Verlag Pharmazeutischer Verlag

DOCUMENT TYPE: Journal LANGUAGE: German

OTHER SOURCE(S): CASREACT 124:176031

GΙ

AUTHOR(S):

AB The novel tricyclic ring systems I (R = CO2Me; R1 = Me, 2-HOC6H4, Ph; X = CH, N) were prepared by reaction of thienopyrazoles II with 1,3-dielectrophiles, such as acetylacetone, dibenzoylmethane, or 1,2,4-dithiazole. Another synthetic route for the preparation of the tricyclic systems, based on pyrazoloazines, was investigated. I and II (R = CO2Me, COPh) exhibited antiulcer activity.

IT 139299-16-4P 139299-18-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(preparation and antipleer activity of this popurazology rimidines and

(preparation and antiulcer activity of thienopyrazolopyrimidines and
-triazines)

RN 139299-16-4 CAPLUS

CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Ph
$$\stackrel{\circ}{\underset{\text{H}_2\text{N}}{\bigcup}}$$
 $\stackrel{\circ}{\underset{\text{N}_2\text{N}}{\bigcup}}$ $\stackrel{\circ}{\underset{\text{N}_2\text{N}}{\bigcup}}$ $\stackrel{\circ}{\underset{\text{N}_2\text{N}}{\bigcup}}$

RN 139299-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

● HCl

L3 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1995:777293 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 123:340045

ORIGINAL REFERENCE NO.: 123:61027a,61030a

TITLE: Aminothieno[2,3-c]pyrazoles and

aminothieno[2,3-b]pyrroles

AUTHOR(S): Gewald, K.; Rennert, S.; Schindler, R.; Schaefer, H. CORPORATE SOURCE: Inst. Organische Chem., Technischen Univ., Dresden,

Germany

SOURCE: Journal fuer Praktische Chemie/Chemiker-Zeitung

(1995), 337(6), 472-7

CODEN: JPCCEM; ISSN: 0941-1216

PUBLISHER: Barth
DOCUMENT TYPE: Journal
LANGUAGE: German

AB The synthesis of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines was described. These compds. were prepared from 3-amino-4-cyano-5-(methylthio)-1,2-dithiol-1-ium iodide as starting material.

IT 139299-12-0P 170953-43-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)

RN 139299-12-0 CAPLUS

CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX NAME)

RN 170953-43-2 CAPLUS

CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX NAME)

IT 170953-44-3P 170953-45-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of thieno[2,3-c]pyrazolamines and thieno[2,3-b]pyrrolamines)

RN 170953-44-3 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carbonitrile, 3,4-diamino- (CA INDEX NAME)

RN 170953-45-4 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxamide, 3,4-diamino- (CA INDEX NAME)

L3 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1992:106287 CAPLUS Full-text

DOCUMENT NUMBER: 116:106287

ORIGINAL REFERENCE NO.: 116:18003a, 18006a

TITLE: Preparation of thieno[2,3-c]pyrazole-3,4-diamines INVENTOR(S): Briel, Detlef; Moschke, Thomas; Wagner, Guenther; Lohmann, Dieter; Hoffmann, Wolfgang; Ploen, Ursula

PATENT ASSIGNEE(S): Karl-Marx-Universitaet Leipzig, Germany

SOURCE: Ger. (East), 6 pp.

CODEN: GEXXA8

DOCUMENT TYPE: Patent LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DD 294485	A5	19911002	DD 1990-340708	19900516
PRIORITY APPLN. INFO.:			DD 1990-340708	19900516
OTHER COHROL (C).	CACDEZ	OT 116.1060	7. MADDAT 116.106007	

OTHER SOURCE(S): CASREACT 116:106287; MARPAT 116:106287

GΙ

$$^{\mathrm{N}}$$
 $^{\mathrm{N}}$ $^{\mathrm{$

- Title compds. I (R = H, Me; R1 = CO2Me, CO2Et, Bz) were prepared by treating thiophenes II (R2 = alkylsulfonyl) with RNHNH2 with or without isolation of the intermediates II (R2 = NRNH2). Thus, II (R1 = Bz, R2 = MeSO2) was prepared from II (R2 = SH) by methylation and oxidation and was treated with MeNHNH2 in MeOH under reflux followed by HCl-MeOH to give 60% I.HCl (R = Me, R1 = Bz).
- IT 139299-12-0P 139299-14-2P 139299-16-4P 139299-18-6P 139299-19-7P 139299-20-0P 139299-21-1P 139299-25-5P 139299-27-7P
- RN 139299-12-0 CAPLUS
- CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl- (CA INDEX NAME)

$$\begin{array}{c} \text{Ph} \longrightarrow \begin{array}{c} \text{O} \\ \text{NH} \end{array}$$

- RN 139299-14-2 CAPLUS
- CN Methanone, (3,4-diamino-1-methyl-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)

- HCl
- RN 139299-16-4 CAPLUS
- CN Methanone, (3,4-diamino-1H-thieno[2,3-c]pyrazol-5-yl)phenyl-, hydrochloride (1:1) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

● HCl

RN 139299-18-6 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

● HCl

RN 139299-19-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

RN 139299-20-0 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, methyl ester, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 139299-19-7 CMF C7 H8 N4 O2 S

$$\begin{array}{c|c} MeO & \stackrel{\bigcirc}{\underset{H2N}{\bigcup}} S & \stackrel{H}{\underset{N}{\underset{N}{\bigcup}}} N \\ \end{array}$$

CM 2

CRN 7664-93-9 CMF H2 O4 S

RN 139299-21-1 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-1-methyl-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 139299-25-5 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

● HCl

RN 139299-27-7 CAPLUS

CN 1H-Thieno[2,3-c]pyrazole-5-carboxylic acid, 3,4-diamino-1-methyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)

● HCl

L3 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2009 ACS on STN ACCESSION NUMBER: 1987:4942 CAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 106:4942
ORIGINAL REFERENCE NO.: 106:927a,930a

TITLE: Nitriles in heterocyclic synthesis. A novel synthesis

of 4-phenacylpyrazole and pyrrolo[2,3-c]pyrazole

derivatives

AUTHOR(S): Abdelrazek, Fathy Mohamed; Erian, Ayman Wahba; Hilmy,

Khalid Mohamed Hassan

CORPORATE SOURCE: Fac. Sci., Cairo Univ., Giza, Egypt

SOURCE: Synthesis (1986), (1), 74-5

CODEN: SYNTBF; ISSN: 0039-7881

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 106:4942

GΙ

- AB PhCOCH2CH(CN)2, prepared from PhCOCH2Br and CH2(CN)2, underwent cyclization with RNHNH2 (R = H, Ph) to give pyrazoles I, which were treated with Cl3CCN to give pyrrolopyrazoles II.
- IT 105576-69-0P 105576-70-3P

RN 105576-69-0 CAPLUS

CN Methanone, (3,5-diamino-1,6-dihydropyrrolo[2,3-c]pyrazol-4-yl)phenyl- (CA INDEX NAME)

RN 105576-70-3 CAPLUS

CN Methanone, (3,5-diamino-1,6-dihydro-1-phenylpyrrolo[2,3-c]pyrazol-4-yl)phenyl- (CA INDEX NAME)

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & &$$

=> log off
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
STN INTERNATIONAL LOGOFF AT 09:59:16 ON 13 JAN 2009